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ABSTRACT 
The tubulysins are a family of nine complex peptides with promising cytotoxic activity against 
multi drug-resistant tumors. This thesis reports a third tubulysin producing strain, Cystobacter sp. 
SBCb004. Although the tubulysin biosynthetic gene clusters appear to be incomplete in both 
SBCb004 and An d48, comparison of the clusters reveals a conserved 11-gene architecture, 
which allowed the assignment of cluster boundaries. Knockout mutagenesis and in vitro assay of 
genes located at both ends of the conserved cluster revealed their involvement and possible 
functions in the tubulysin pathway. Pretubulysin was identified from both natural producer strains, 
confirming its intermediacy in the pathway. Using a combination of feeding studies and high-
resolution tandem mass spectrometry, An d48 and SBCb004 were found to biosynthesize 32 
additional tubulysin derivatives. Using Red/ET recombineering, the entire tubulysin core gene 
cluster from strain SBCb004 was reconstituted and successfully expressed in heterologous host 
strains Pseudomonas putida and Myxococcus xanthus. Finally, BLAST analysis of the SBCb004 
genome data was carried out to identify candidate monooxygenases, whose involvements in 
tubulysin assembly were evaluated using a combination of knockout mutagenesis and 
heterologous expression.  
 
 II 
 
ZUSAMMENFASSUNG 
Tubulysine stellen eine Familie von neun komplexe Peptiden dar, welche viel versprechende 
zytotoxische Eigenschaften gegen multiresistente Tumore aufweisen. In dieser Arbeit wird ein 
dritter Stamm beschrieben, welcher Tubulysine produziert (Cystobacter sp. SBCb004). Obwohl 
die Tubulysin-Biosynthesegencluster aus SBCb004 und An d48 unvollständig erscheinen, zeigt 
ein Vergleich der Gencluster eine konservierte Architektur von elf Genen auf, wodurch die 
Grenzen des Clusters definiert werden konnten. Über Geninaktivierungsstudien und in vitro 
Assays konnte die Beteiligung und mögliche Funktion von Genen, welche an beiden Enden der 
Gencluster in konservierter Form gefunden wurden, aufgezeigt werden. Prätubulysin wurde in 
den Extrakten beider natürlichen Produzentenstämme identifiziert und so als 
Biosyntheseintermediat bestätigt. Zudem wurde basierend auf der Kombination von 
hochauflösender Massenspektrometrie und Fütterungsexperimenten nachgewiesen, dass An d48 
und SBCb004 zusammen 32 zusätzliche Tubulysinderivate herstellen. Der Tubulysin-
Biosynthesegencluster aus Stamm SBCb004 ausgehend mittels Red/ET Recombineering 
rekonstituiert und dann heterolog in Pseudomonas putida und Myxococcus xanthus exprimiert. 
BLAST Analysen des Genoms von SBCb004 zeigten die Präsenz von multiplen 
Monooxygenasen auf, deren Beteiligung an der Tubulysinbiosynthese durch eine Kombination 
von Inaktivierungsmutagenese und heterologer Expression studiert wurde.  
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1   INTRODUCTION 
 
 
1.1 Natural products in drug discovery 
 
   Even thousands of years ago, man was using boiled herb extracts as medicines to treat disease. 
Insights into the active principles that these extracts contained started to emerge two hundred 
years ago, when Friedrich Sertürner identified morphine as the pain-relieving principle from the 
poppy Papaver somniferum L [1-3]. Alexander Fleming discovered that the fungus Penicillium 
notatum produced a metabolite capable of killing bacteria, and the active agent pencillin was 
isolated shortly after that in 1928 [4]. The identification of individual compounds with biological 
activities represented a major milestone in modern medicine, inaugurating a new era in natural 
product research. Since then, natural products have been established as invaluable sources for 
novel drugs and drug-leads. The primary reason for the utility of these compounds is that they are 
privileged structures selected over millions of years by evolution to interact with a variety of 
targets in a specific manner [5]. Today, approximately 50% of pharmaceuticals in clinical use are 
natural products or their derivatives (Figure 1.1). 
 
   Natural products are produced by plants, fungi, and both terrestrial and marine microorganisms. 
These secondary metabolites exhibit a wide variety of biological activities, including anti-
bacterial, anti-fungal, antiparasitic and anti-cancer properties [6-9]. In addition to their many 
applications in human therapy, they are also used in agriculture as plant growth regulators, 
herbicides and insecticides [10]. A high proportion of these compounds are polyketides, 
nonribosomal peptides, or hybrids of both classes. In bacteria, the biosynthetic enzymes are 
usually encoded by genes that are clustered together in the genome, facilitating the identification 
and analysis of the biosynthetic pathway [11]. The knowledge gained can be used to inform 
targeted manipulation of the biosynthesis towards the generation of structural derivatives, either 
through genetic modification of the primary or secondary metabolism of the producing organisms 
or through the use of individual enzymatic activities in vitro [12; 13].  
 
  
Figure 1.1 Examples of bioactive 
(1) Erythromycin (polyketide, 
Streptomyces roseosporus); (3) 
Rapamycin (polyketide-nonribosomal polypeptide hybrid
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of microbial producers, and s
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1.2   Myxobacteria – 
 
natural products derived from bacteria. 
Saccharopolyspora erythrea); (2) Daptomycin (nonribosomal polypeptide
Vancomycin (nonribosomal polypeptide, Amycolatopsis 
, Streptomyces hygroscopicus
product in the clinical setting, there remains a pressing 
to the increase in multi
lack of highly effective therapeutics for many, and the side effects 
ines [10; 14]. Efforts have been made to identify new groups 
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.   
a promising source for novel natural products
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   Myxobacteria are obligate, aerobic, chemotrophic, Gram-negative mesophilic δ-proteobacteria. 
The cells are typically rod-shaped, which are 4−12 microns in length and 0.7−1.2 microns in 
width. To date, approximately 7500 different myxobacteria have been isolated, and novel strains, 
species and even families are continually being discovered [16; 17]. The myxobacteria are united 
in the order Myxococcales, and further divided in three suborders: Cystobacterineae, 
Sorangiineae and Nannocystineae [18]. They occupy a wide range of habitats, such as soil, the 
bark of trees, decaying plant materials, herbivore dung, and the marine environment [16; 19; 20].  
 
   A special feature of myxobacteria is their ability to move smoothly on solid surfaces by gliding 
or creeping. During swarming, they leave a thin film of mucus which exhibits a characteristic 
surface wave pattern [21]. Due to their ability to coordinate their movements, the myxobacteria 
additionally exhibit an extent of ‘social behavior’ which is unique among the bacteria. Under 
starvation conditions, they aggregate to form characteristic multi-cellular structures called fruiting 
bodies [22; 23]. These structures can exhibit different shapes and colors, depending on the species. 
Within the fruiting bodies, cells begin as rod-shaped vegetative cells, and develop into rounded 
myxospores with thick cell walls. The myxospores, which are analogous to spores produced by 
other organisms, are meant to survive until nutrients are more plentiful. The fruiting process is 
thought to benefit myxobacteria by ensuring that cell growth is resumed by a group of 
myxobacteria, rather than by isolated cells. The shape of the fruiting bodies, which range from 
simple spherical aggregates to palm-shaped structures, is an important means by which the 
myobacteria can be classified. Another defining feature is that the myxobacteria can access a 
diversity of biological macromolecules (e.g., cellulose) as food sources via the secretion of 
extracellular enzymes, and can prey on whole microorganisms such as fungi and bacteria [24; 25]. 
Taken together, these behavioral features distinguish the myxobacteria from most other bacteria.  
 
   Another unique characteristic of the myxobacteria is the size of their genomes. Relative to other 
bacteria, the myxobacteria have extremely large genomes (about 9–13 Mbp). In fact, the genome 
of Sorangium cellulosum (S. cellulosum) at 13.0 million nucleotides, is  the largest known 
bacterial genome (as of 2008) [26-28]. It has recently been noted that there is a direct correlation 
between the size of bacterial genomes and the ability to produce secondary metabolites [29]. 
Indeed, the sequenced myxobacterial genomes reveal a high number of gene clusters putatively 
encoding secondary metabolite biosynthesis, for example strain S. cellulosum harbors 17 gene 
clusters and Myxococcus xanthus (M. xanthus) harbors 18 gene clusters [26; 30]. 
 
 4 
 
   Even prior to the advent of whole-genome sequencing, the myxobacteria had been identified as 
a promising source of natural products (selected examples of myxobacterial secondary 
metabolites are shown in Figure 1.2). Within the last two decades, at least 100 distinct core 
structures and approximately 500 derivatives have been characterized from myxobacteria [25]. 
From analysis of the sequenced genomes, however, it is clear that much of myxobacterial 
metabolism remains to be characterized, and that genome mining of the strains should provide 
access to large number of new structures [29; 31; 32]. Of particular interest, myxobacterial 
natural products exhibit rare or wholly novel modes of action relative to other compounds of 
bacterial origin, features which make them attractive starting points for drug discovery. For 
example, argyrin acts as a potent proteasome inhibitor [33], stigmatellin and soraphen both show 
antifungal bioactivity [34; 35], tubulysin, disorazol, and epothilone all interact with cytoskeleton 
[36-38]. These findings mark the myxobacteria as a promising source for novel drug leads [25].  
 
 
Figure 1.2 Selected examples of myxobacterial secondary metabolites. 
(1) Epothilone B (antitumor, Sorangium cellulosum); (2) Argyrin A (antitumor, Archangium gephyra); (3) 
Soraphen A (antifungal, Sorangium cellulosum); (4) Stigmatellin A (antifungal, Stigmatella aurantiaca); (5) 
Tubulysin A (cytotoxic, Archangium gephyra). 
 
 
   Among the most promising myxobacterial natural products are several compounds which target 
the microtubule network of eukaryotic cells. Due to their various effects on the network, they can 
be divided into two groups: either they stabilize microtubules and induce polymerization, or they 
destabilize them and cause degradation of the microtubule network. Both effects inevitably lead 
to the collapse of microtubule-dependant cellular processes, and the eventual induction of 
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apoptosis. The most famous myxobacterial representatives of these anti-mitotic compounds are 
the epothilones, isolated from the myxobacterium S. cellulosum [39]. Indeed, a semi-synthetic 
epothilone B derivative (Ixabepilone®) was, in 2007, the first myxobacterial natural product to be 
approved for clinical use by the FDA for the treatment of aggressive breast cancer (Figure 1.2A). 
Epothilone has been shown to have a similar mechanism of action as that of Taxol, but exhibits 
much stronger bioactivity, and also induces cell death in Taxol-resistant cancer cell lines. Other 
myxobacterial compounds which interact with the cytoskeleton include tubulysin and disorazol 
which destabilize their tubulin target (Figure 1.2) [40], and rhizopodin, which binds to actin 
preventing its polymerization [37; 38; 41]. Of particular note, the bioactivity of tubulysin is 
higher than that of both Taxol and epothilone [42].  
   
 
1.3   Polyketide and nonribosomal peptide biochemistry 
 
   Many myxobacterial secondary metabolites are polyketides and nonribosomal polypeptides, 
which are assembled by gigantic multienzymes called polyketide synthases (PKS) and non-
ribosomal peptide synthetase (NRPS), respectively.  
 
1.3.1  PKS biochemistry 
   The synthesis of polyketides is comparable to that of the fatty acids, as the two pathways have 
strong homologies both in the nature of the chemistry used in chain extension from a common 
pool of simple precursors and in the character of the enzymes that are used for chain assembly. 
Based on the mode of catalysis and the structure of the biosynthetic proteins, PKS are usually 
classified into type I, II and III, although there are increasing examples of systems which are 
formally hybrids of several classes [43]. 
    
   Type I polyketide synthases are multifunctional enzymes that are organized into modules 
[44]. Each module contains the three core domains required for one round of extension of the 
growing polyketide chain with a specific carboxylic acid building block. One of the essential 
domains is the acyl carrier protein (ACP) domain, which serves as a point of covalent attachment 
of the intermediates to the PKS as well as shepherding the chains to the various catalytic domains 
within the modules. In order to be functional, the ACP domains must be post-translationally 
activated by a phosphopantetheinyltransferase (PPTase). These enzymes catalyze the transfer of 
the 4’-phosphopantetheine (Ppant) moiety of a coenzyme A (CoA) to a highly conserved serine 
  
residue of the ACP, converting the carrier protein domain from 
holo form [45]. During chain
this phosphopantetheine arm as
shuttle the intermediate to all of the catalytic domains
Figure 1.3 Post-translational modification of the ACP/PCP domain by a PPTase. 
The PPTase catalyzes the transfer of Ppant from CoA to a conserved serine in the carrier protein domain, 
converting the inactive apo domain
 
 
   The other two core domains in PKS are the
The role of the AT domain in chain extension modules is to
(such as malonyl-CoA and methylmalonyl
also an AT domain present in the first (‘loading’) module of the PKS, which is responsible for 
choosing a starter unit, such as 
autoacylation with the building block, and then transfer the substrate to the adjacent ACP. 
Carbon-carbon bond formation between the newly recruited extender unit and the growing chain 
is catalyzed by the KS domain. This condensati
intermediate tethered to a conserved cysteine of the KS domain, and a carbanion nucleophile 
generated by KS-catalyzed decarboxylation of the bound extender unit.
 
its inactive apo
 assembly, the intermediates are bound to the terminal thiol group of 
 a thioester, and the Ppant acts as swinging arm that is able to 
 (Figure 1.3). 
 
 to the active holo form. 
 acyltransferase (AT) and the ketosynthase 
 selects short chain 
-CoA) as building blocks for the biosynthesis. There is 
acetyl-CoA or propionyl-CoA. All ATs first catalyze their 
on reaction occurs between the polyketide 
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 form to its active 
 
 
(KS). 
dicarboxylic acids 
  
Figure 1.4 Schematic overview of PKS biochemistr
AT domains within the loading module and the first extention module select their respective acyl
monomers and catalyze the transthiolation of these substrates to the downstream ACP domains. In the next 
step, the starter unit is transferred 
Subsequently decarboxylative condensation catalyzed by the KS domain occurs
between the starter and extender units, 
this particular case).  
 
 
   The β-carbonyl groups of the polyketide
several optional domains within
dependent ketoreductase (KR) 
alcohol can then be dehydrated to the double bond by a 
further NADPH-dependent 
enoylreductase (ER) (Figure 1.5)
shuttled from module to module until the biosynthesis is completed, and the intermediate is 
cleaved from the multienzyme
macrocyclization (Figure 1.4).
 
y.  
from the loading ACP to the KS of the first exten
, forming a
resulting in the elongated ACP-bound intermediate
 that result from the condensation 
 the ‘reductive loop’ of the module [43]. 
domain can take the carbonyl to the state of an alcohol. The 
dehydratase (DH) domain
reduction to the fully-reduced methylene, catalyzed by an 
. This sequence of reactions is repeated as the growing chain is 
 by the terminal thioesterase domain, either by hydrolysis or 
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-CoA 
sion module. 
 C–C bond 
 (a diketide in 
can be reduced by 
First, the NADPH-
, followed by 
  
 
Figure 1.5 Optional β-carbon processing catalyzed by the KR, DH and ER domains. 
 
 
   In type I PKS, although chain extension modules are typically used singly, there are also several 
exception examples that the PKS modules act iteratively during the biosynthetic process, such as 
the pathways of stigmatellin in 
[47]. The molecular basis for this iterative behavior is presently unknown, but it is reminiscent of 
the natively iterative type I PKS from fungi  
 
   In bacterial type II polyketide 
which must associate into a multienzyme complex
produce polycyclic, aromatic metabolites
[44]. In type III PKS systems, the catalytic activity of a single active site accomplishes 
reactions necessary for the biosynthesis, including decarboxylation, condensation, cyclization and 
aromatization reactions. Unlike the other
ACP- bound intermediates as substrates 
 
1.3.2  NRPS biochemistry 
   Nonribosomal peptide synthetases
synthases, in that they also comprise 
extension of the growing chain
systems, a minimal NRPS module 
(PCP), adenylation (A), condensation (C) 
Stigmatella aurantiaca [46], and the DKxanthene in 
[48].  
synthases, the catalytic domains are present as discrete proteins 
. The biosynthetic machinery acts iteratively 
 using malonyl-CoA as the substrate
 PKS types, type III PKS use CoA
[49-51]. 
 exhibit a similar organization as the
modules dedicated to initiation of the biosynthesis
 and termination of chain assembly [52]. By analogy to the PKS 
also consists of three core domains: peptidyl carrier protein 
(Figure 1.6). The A domain is responsible for choosing 
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M. xanthus 
 to 
 for chain extension 
all 
-esters instead of 
 type I  polyketide 
, 
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the specific amino acid to be added to the chain. It activates the residue to the aminoacyl 
adenylate in an ATP-dependent reaction, and then transfers it to the adjacent PCP domain within 
the module, forming the respective aminoacyl-S-PCP. The substrate specificity of the A 
domain is supposed to be determined by eight non-conserved amino acids within the overall 
hydrophobic binding pocket [53-55]. Notably, the specificity of the A domains is not restricted to 
the 20 proteinogenic amino acids, as they can also recognize and activate a much wider variety of 
nonproteinogenic amino and aryl acids as building blocks [56]. This biosynthetic feature 
contributes to the high structural diversity within this class of compounds. Following substrate 
selection, the C domain catalyzes the nucleophilic attack of the downstream amino group on the 
aminoacyl or peptidyl moiety bound to the PCP of the upstream module, resulting in a new 
peptide bond.  
 
   As in PKS systems, optional tailoring domains are also present within NRPS modules, which 
again enhance the structural diversity of the polypeptide products. These modification domains 
include the epimerization (E), N-methylation (N-MT), oxidation (Ox) , heterocyclization (HC), 
monooxygenase (Mox), reduction (R) and formyltransferase (F) domains [57]. The N-MT domain 
carries out an S-adenosyl-methionine (SAM) dependent reaction to transfer a methyl group onto a 
nitrogen atom of the intermediate, a reaction which occurs prior to the condensation (Figure 
1.7A). The function of epimerization domains is to convert the L-amino acids into their D-forms, 
which occurs after amide bond formation (Figure 1.7C). The HC domain is a variant of a C 
domain. In addition to peptide bond formation, HC domains catalyze the heterocyclization of the 
side chains of the amino acids cysteine, serine and threonine onto the peptide backbone: attack of 
the sulfhydryl group of cysteine or the hydroxyl group of serine and threonine on the adjacent 
peptide carbonyl results in five-membered hydrolytically labile thiazoline or oxazoline rings. 
Subsequent oxidization by an FMN-dependent Ox domain results in formation of stable thiazole 
and oxazole rings (Figure 1.7B). The process of chain extension and modification is repeated 
until the intermediate reaches the last module where it can be cleaved from the multienzyme by a 
TE domain as a linear or cyclic product [58], or alternatively released by reduction by an R 
domain to form the aldehyde or alcohol [59]. 
 
  
 
Figure 1.6 Schematic overview of NRPS biochemistry. 
(A) Selection and activation of a specific amino acid by the A domain. ATP is consumed in the activation 
reaction, and the aminoacyl group of the 
(B) The C domain catalyzes a condensation reaction 
between two adjacent aminoacyl
elongation of the chain by a single amino acid.
(C) The TE domain releases 
terminate the assembly process.
 
 
 
resulting aminoacyl-AMP is transferred to the PCP domain. 
which results in formation of a
-S-PCP intermediates.  Passage from one module to the next results in 
 
the peptide from the multienzyme either by hydrolysis or cyclization to 
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 new peptide bond 
the 
  
 
Figure 1.7 Reactions of several NRPS modification domains. 
(A) N-methylation catalysed by an 
(B) Formation of a thiazole ring catalyzed by HC and Ox domains. After carrying out the condensation 
between two aminoacyl intermediates, the HC domain facilitates the attack of an internal nucleophilic (in 
this case, a cysteine) on the adjacent carbonyl, 
Subsequently an Ox domain can act on the thiazoline, converting it to the fully
using FMN as a hydride acceptor. 
(C) E-domain catalyzed epimerization. 
 
 
1.3.3  Post-assembly line modifications
   Discrete enzymes, referred to as tailoring enzymes, 
metabolites after they release from the PKS
genes encoding these tailoring enzymes are part of the biosynthesis clusters, allowing coupled 
control of their transcription. 
bioactivity of the natural products. 
 
   PKs in actinomycetes are often decorate
and methyl groups [43; 62]
 
N-MT domain.  
followed by dehydration to yield the thiazoline. 
-reduced aromatic thiazole 
Domains that are involved in a specific catalytic step are colored i
 
 
are able to modify the secondary 
-NRPS multienzyme complex [60; 61]
These post-assembly line modifications are often responsible for the 
 
d with additional moieties, such as sugars, hydroxyls 
. In NRPS system, the typical modifications are 
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n grey. 
. Generally the 
carried out by cis 
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acting domains (such as epimerization, methylation and heterocyclization domains that are 
integrated in the NRPS megasynthetases) during assembly of their scaffold [57], while other post-
modifications are mostly catalyzed in trans by tailoring enzymes [60]. As a classic example, the 
biosynthesis pathway of vancomycin incorporates the post-modifications of glycosylation, 
halogenation, oxidative cross-linking, and hydroxylation [60; 63]. Other examples of 
glycosylation include erythromycin [64], novobiocin [65], chivosazol [66] and sorangicin [67]. 
Halogenase exists in the biosynthetic gene cluster of Syringomycin E [60], chondramides [68], 
and chondrochloren [69]. Furthermore, hydroxylation, methylations and acylations of natural 
products have also been observed [70].  
 
 
1.4   Heterologous expression of natural product pathways through 
Red/ET recombination 
 
   The biological activities of natural products are usually structure related. Thus interests are 
stimulated in using genetic engineering of the biosynthetic pathways to produce analogues for 
evaluation as drug candidates. But it is always difficult of carrying out such manipulation in the 
native producing strains, prompting the need for heterologous expression systems in more 
amendable host strains. Over the last decade, a number of natural product biosynthetic pathways 
have been heterologously expressed with the aid of Red/ET recombination. In principle, this 
technique allows the assembly and subsequent transfer of large biosynthetic gene clusters from 
the natural producer strain into heterologous hosts which are genetically more tractable and easily 
cultivated. It also provides a platform for the detailed investigation of complex biosynthetic 
mechanisms, allows  identification of the products of silent biosynthetic gene clusters, and the 
generation of novel analogs through biosynthetic engineering in the genetically tractable E. coli 
[29; 32; 71-75]. The method is thus gaining increasing interest in both biotechnology and drug 
discovery [76; 77]. 
 
   Red/ET recombination relies on homologous recombination in vivo in a specific strain of E.coli. 
In principle, as the homology regions upon which the technique relies can be chosen freely, any 
position on a target molecule can be specifically altered in a precise manner, regardless of DNA 
size. These qualities make the Red/ET recombination technique a revolutionary DNA engineering 
platform that is capable of engineering large DNA molecules (e.g. cosmids or BACs), and which 
allows for a wide range of DNA modifications (such as insertions, deletions, substitutions, 
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fusions, point mutations, direct cloning and subcloning) at any chosen position [78]. In Red/ET 
recombination, target DNA molecules are precisely altered by homologous recombination in the 
E. coli strains that express the phage-derived protein pairs RecE/RecT from the Rac prophage or 
Redα/Redβ from λ phage (the pairs are equivalent in terms of function). RecE and Redα are 
5'→3' exonucleases, while RecT and Redβ are both DNA annealing proteins. A functional 
interaction between RecE and RecT, or between Redα and Redβ is necessary to catalyse the 
homologous recombination reaction. The process is assisted by λ-encoded Gam protein, which 
inhibits the RecBCD exonuclease activity of E. coli (Unlike in yeast, linear dsDNA is unstable in 
E.coli because of the activity of RecBCD) (Figure 1.8) [71; 79]. The homologous recombination 
occurs through homology regions, termed homology arms (hm). which are regions of DNA 
sequence that are shared by the two molecules. The modification cassette is typically a small 
DNA fragment generated by PCR, which harbors the sequence to be introduced and a selection 
marker, flanked by homology arms. The target DNA can be a gene locus on the E. coli 
chromosome, or any other stretch of DNA in a BAC or plasmid vector (Figure 1.9) [71; 79]. 
 
 
Figure 1.8 Mechanism of Red/ET recombination. 
A double-stranded break repair (DSBR) is initiated by the recombinase protein pairs, RecE/RecT or 
Redα/Redβ. First Redα (or RecE) digests one strand of the DNA from the DSB, leaving the other strand as 
a 3´ single-stranded DNA overhang. Then Redβ (or RecT) binds to and coats the single strand. The protein-
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nucleic acid filament then aligns with the homologous DNA. Once aligned, the 3´- end becomes a primer 
for DNA replication. The diagram was reproduced from www.genebridges.com. 
 
 
 
Figure 1.9  Crossover step in Red/ET recombination. 
The crossover step occurs between a modification cassette and the target DNA (e.g. a plasmid or the E. coli 
chromosome). The diagram was reproduced from www.genebridges.com. 
 
 
   The general overview of the strategy for cloning and heterologous expression of large natural 
product assembly lines is shown in Figure 1.10 [71]. First, in order to obtain the natural product 
biosynthetic gene cluster, a BAC or cosmid library is screened for DNA harboring parts of the 
gene cluster. As it is often the case that the large biosynthetic clusters are located on multiple 
BACs/cosmids, Red/ET recombineering in E. coli is then used to reconstitute the complete gene 
sets on one heterologous expression construct. The resulting construct harboring the entire 
pathway can be further modified in E. coli by recombineering, in order for example to add genes 
that are needed for transformation into the desired heterologous host, promoters and other control 
elements required for  efficient expression, etc. The final construct can then be transferred into 
suitable heterologous host or hosts, and growth extracts screened for successful production of the 
desired metabolite [71].  
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Figure 1.10  General strategy for the heterologous expression of natural product biosynthetic gene 
clusters. 
The figure was reproduced from reference [71]. 
 
 
   There are several specific challenges associated with the heterologous expression of polyketide 
and nonribosomal peptide biosynthetic pathways. For example, the host strain must be able to 
fold and post-translationally activate the gigantic multienzymes and thus a PPTase of suitably 
broad specificity must be present. Furthermore, the biosynthesis requires the presence of a 
specific pool of substrates, potentially including coenzyme A-activated short-chain carboxylic 
acids, proteinogenic and specific non-proteinogenic amino acids, short-chain fatty acids, and 
sugars. It is often necessary to adapt fermentation protocols in order to optimize production by 
ensuring that the required substrates are available in adequate amounts at the correct time. If 
antimicrobials or toxic agents are to be produced, it is necessary to include inducible promoters so 
that the effects of the metabolites on the growth of the host can be minimized.  
 
   One such inducible promoter system is that is based on tetracycline (pTet promoter). In Gram-
negative bacteria, the Tet repressor protein (TetR) regulates the transcription of a family of 
tetracycline resistance genes [80-82]. In this system, the gene tetA encodes the tetracycline 
resistance protein which is a membrane-spanning H+–[tet–Mg]+ antiporter. The 81 bp sequence 
between tetA and tetR habors the promoter of tetA, pTetA, two overlapping promoters of tetR, 
pTetR1 and pTetR2, and two highly homologous control gene sequences tetO1 and tetO2 (Figure 
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1.11). In the absence of the inducer tetracycline, TetR protein dimmers bind to the two operators 
tetO1 and tetO2, shutting down transcription of the downstream resistance gene tetA. TetR has 
high affinity to tetracycline. Therefore, once tetracycline enters into the cell, the TetR protein will 
complex with the tetracycline in preference to the tetO sequence region. This binding lifts the 
inhibition on the pTetA promoter, allowing for expression of TetA. In summary, the regulatory 
system based on tetR and the 81 bp tetO control region can be used to regulate transcription of 
downstream genes via induction by tetracycline.   
 
 
Figure 1.11  pTet promoter regulation system.  
(A) The 81 bp gene sequence containing the promoter pTetA and pTetR as well as two operators, tetO1 and 
tetO2.  
(B) Principle of the regulation of the pTet promoter. 
The figure was reproduced from reference [81]. 
 
 
   Taking all these challenges into account, it is not surprising that to date, only a few bacterial 
strains have been demonstrated as suitable heterologous expression hosts, including E. coli, 
Streptomyces, Pseudomonads, Bacilli, and the myxobacteria [75]. Nonetheless, heterologous 
expression has been used successfully with a number of natural product assembly lines, including 
those responsible for polyketides, non-ribosomal polypeptides and their hybrids. Examples 
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include the expression of some small type II PKS gene clusters in Streptomyces strains (e.g. 
medermycin, griseorhodin A, aloesaponarin II, precursors of kanamycin) [83-86], landomycin A 
and prodigiosin in Streptomyces fradiae and Erwinia carotovora strains [87; 88], daptomycin in 
Streptomyces roseosporus [89], phenalinolactone in Streptomyces strains [90], yersiniabactin in E. 
coli [91; 92], myxochromide and myxothiazol in Pseudomonas putida (P. putida) and the 
myxobacterium M. xanthus [71; 93; 94], and the epothilones in Streptomyces coelicolor, M. 
xanthus and E. coli [95-98], et al. 
 
 
1.5   The tubulysins – targets for biosynthetic investigation and 
heterologous expression 
 
   Tubulysins are active against a wide variety of cancer cell lines (ovarian, breast, prostate, colon, 
lung and leukemia) within the NIC-60 cell line panel, including multi drug-resistant tumors [99] 
(Figure 1.11). They are among a handful of natural products which interact with the eukaryotic 
cytoskeleton, inhibiting the polymerization of tubulin at very low concentrations (<50 pg ml-1) 
[37; 40]. Notably, their growth inhibition potential exceeds that of the anti-cancer drugs 
epothilone, vinblastine, and taxol, by 20–1000 fold [100]. Mode-of-action studies have 
demonstrated that the tubulysins disrupt microtubule assembly [37], and that they also show anti-
angiogenic effects [101]. Together, these properties make the tubulysins attractive lead structures 
for development as anti-neoplastic agents by both academic and industrial sectors.  
 
 
Figure 1.12  Activity of tubulysin against PtK2 cancer cells.  
(A) Microtubules of control cells. The cells were fixed and immunostained for tubulin. Green: microtubule 
network; blue: cell nuclei. 
(B) Incubation of Potoroo kidney (PtK2) cells with tubulysin A (50 ng/ml) for 24 hr. After 24 hours, the 
cell nuclei begins to fragment and the microtubule network is completely degraded .  
The figures were reproduced from reference [102]. 
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   The first nine-members of the tubulysin family (Figure 1.12) were discovered by Höfle, 
Reichenbach and their co-workers from myxobacterial strains Angiococcus disciformis An d48 
and Archangium gephyra Ar 315, using bioactivity-guided screening with L929 mouse fibroblasts 
[40; 100]. They were subsequently identified in extracts of additional myxobacteria, including 
Stigmatella and Cystobacter. The shared molecular core comprises five amino acids (N-methyl 
pipecolic acid (Mep), isoleucine (Ile), valine, cysteine and phenylalanine or tyrosine), and two 
units of acetate. In the synthetic literature, valine, cysteine and one unit of acetate have been 
grouped together into a structural unit referred to as tubuvaline (Tuv), while the acetate chain-
extended forms of phenylalanine or tyrosine are designated as tubuphenylalaline (Tup) and 
tubutyrosine (Tut), respectively. All of the structures include an acetoxy moiety, but exhibit 
variable functionality (R1) within the Tuv bis-acyl N,O-acetal substituent. SAR studies using 
synthetic analogues of the most potent tubulysin, tubulysin D, have begun to identify the essential 
structural features underlying its cytotoxicity, as well as suggesting strategies for optimizing the 
metabolite’s pharmacological properties [103-108]. Taken together, these data reveal a surprising 
tolerance to structural modification, encouraging efforts to synthesize simplified variants of the 
tubulysins for evaluation as anticancer agents. For example, replacing the chemically labile N,O-
acetal and stereogenic acetate groups of tubuvaline with stable alternatives resulted in only a 
minor loss of potency [104]. 
 
 
Figure 1.13  The nine tubulysins known when this work was initiated.   
 
 
   Angiococcus disciformis An d48 is known to produce four tubulysins, the tubulysins D, E, F 
and H [100]. Sequencing of the approximately 40 kb tubulysin gene cluster within the strain 
revealed that tubulysin assembly is catalyzed, as expected, by a molecular assembly line, 
consisting of  five NRPS modules and two PKS modules [102]. However, the gene set does not 
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incorporate any obvious functions for carrying out the required post-assembly line oxidation and 
acyl transfer reactions. 
 
 
1.6   Outline of this work 
 
   The goal of the work described in this thesis was to deepen our understanding of the tubulysin 
biosynthetic pathway. Studies were carried out with the aim of obtaining further insights into 
pathway initiation and post-assembly line aspects, as well as identifying novel tubulysin 
derivatives. A second major goal was to facilitate the eventual engineering of the gene cluster 
towards the generation of bioactive derivatives. 
 
   The identified tubulysin core biosynthetic gene cluster from strain An d48 is incomplete due to 
the missing post-modification enzymes. As comparative cluster analysis is often informative, the 
first specific aim of this work was to identify the tubulysin gene cluster in a second myxobacterial 
strain, Cystobacter sp. SBCb004. I wanted to determine the cluster boundaries via comparative 
analysis of the two clusters, and also wanted to find those missing gene. Detailed comparison of 
the two clusters allowed determination of the cluster boundaries, supporting a role for several 
conserved genes (orfs 1, 2, 17 and 18) whose participation in the biosynthesis was not obvious 
based on automated assignment of gene function. In addition, the more amenable SBCb004 strain 
was then expected to provide a more convenient platform for further investigation of the 
tubulysin biosynthetic pathway. As proof-of-principle, an attempt was made to boost tubulysin 
yields in the strain by manipulation of the promoter region.  
    
   Among the auxiliary genes, the first target for investigation was the cyclodeaminase-encoding 
gene tubZ, whose protein product was expected to furnish the unusual amino acid L-pipecolate, 
the presumed starter unit for tubulysin assembly. This activity was confirmed by analysis in vitro 
of recombinant TubZ produced in E. coli. TubZ’s role was also explored by inactivation 
mutagenesis in strains SBCb004 and An d48, which demonstrated that the protein participates in 
the pathway, but is not essential for tubulysin biosynthesis. A similar inactivation approach was 
used to investigate the function of genes orf1, orf2, orf17 and orf18. Although the experiments 
with orfs 1 and 2 did not clearly reveal their function, they nonetheless showed that the protein 
products play a role in tubulysin biosynthesis. Inactivation of orfs 17 and 18, on the other hand, 
demonstrated their explicit involvements, and also provided clues for the function of acyl 
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hydrolase in the tubulysin assembly. In addition, this work provided support for the role of TubA 
as one of the missing acyl transferases. 
 
   During the course of this work, new metabolites, pretubulysin A or D, were discovered in 
extracts of wild type SBCb004 and An d48. This result prompted reanalysis of the extracts by 
HPLC-MS/MS for the presence of additional metabolites which may have escaped detection in 
earlier experiments. This work resulted in the identification of 30 additional tubulysin derivatives, 
resulting from skipping of specific catalytic domains or even an entire PKS module, or from the 
missing of glycerol hydrolysis carried out by the patatin genes, illustrating the inherently 
diversity-oriented nature of the pathway. As pretubulysin has been demonstrated to retain good 
bioactivity [109], these additional simplified analogues of tubulysin molecules could find interest 
as drug leads.  
 
   To facilitate the engineering of such tubulysin derivatives, the next goal of this thesis was to 
reconstitute the entire tubulysin gene cluster using Red/ET recombineering technology, and to 
heterologously express it in host strains P. putida and M. xanthus. The established heterologous 
expression system was then used to confirm the gene inactivation results obtained with the natural 
hosts strains An d48 and SBCb004.  
 
   Furthermore, I aimed to use BLAST analysis of the SBCb004 genome to identify possible 
candidate monooxygenases. Then coupled with inactivation mutagenesis and heterologous 
expression, the possible candidate could be studied in detail. Inactivation of identified P450 gene 
633P1 in SBCb004 supported its role as one of the missing oxidative functions, although addition 
of the gene to the heterologous expression construct did not result in oxidized pretubulysins.   
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2   MATERIAL AND METHODS 
 
 
2.1   Chemicals 
All chemicals used in this work were obtained from the manufacturers, at analytical grade. 
 
Table 2.1  Chemicals used in this work  
Chemical product Manufacturer 
Acetone 
Acetonitrile 
Chloroform 
Ethanol 
Ethyl acetate 
Hexane 
Methanol 
Magnesium sulfate 
2-Propanol 
Succinic acid 
Sigma Aldrich 
 
Ammonium acetate 
Sodium-EDTA 
Potassium hydroxide 
Fluka 
 
Acetic acid 
Boric acid 
Bromphenolblue 
Calcium chloride-di-hydrate 
Glucose monohydrate 
Glycerin 
Magnesium chloride 
Magnesium sulfate hepta-hydrate 
Potassium acetate 
Potassium hydrogen phosphate 
Merck 
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Potassium sulfhate 
Sodium chloride 
Sodium citrate-di-hydrate 
Sodium hydroxide 
Bacto agar 
Casitone 
Casaminoacids 
Malt extract 
Tryptone 
Peptone 
Yeast extract 
Becton Dickinson and Co., USA 
 
Ammonium persulfate 
5-Bromo-4-chloro-3-indolyl-_-D-
galactopyranoside 
Coomassie Brilliantblue 250R 
Dithiothreitol 
Ethidium bromide solution (1%) 
Formamide 
Maleic acid 
Sodium dodecyl sulfate (SDS) 
Rotiphorese®Gel 30 
TEMED 
Triton X-100 
ROTH 
 
BSA (Bovine Serum Albumin) New England Biolabs 
XAD 16 adsorber resin Rohm and Haas 
 
 
 
2.2   Enzymes, kits and markers 
All the enzymes in this work were used according to the manufacturers’ protocols. 
 
Table 2.2  Enzymes, kits and markers  
Product Manufacturer 
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DNA ladder 
T4 DNA ligase 
Page RulerTM Prestained Protein Ladder 
Page RulerTM Protein Ladder 
Shrimp alkaline phosphatase 
Restriction endonucleases 
Plasmid purification kit 
Nucleotides 
MBI Fermentas 
 
Taq Ploymerase Quiagen 
Phusion DNA Polymerase Finnzymes 
KOD DNA Polymerase Novagen 
Topo TA Cloning® Kit 
Gel-Dry™ Drying Kit 
Invitrogen 
 
Proteinase K 
Lysozyme 
Roth 
 
DIG labeleld DNA Molecular Weight Marker III 
DIG-Labeling and Detection Kit 
DIG-Blocking solution 
DIG EasyHyb 
DIG PCR Labeling Mix 
Roche 
 
BugBuster® Protein Extraction Reagent Novagen 
Gigapack® III Gold Packaging Extract Stratagene 
 
 
 
2.3   Buffers and solutions 
 
Table 2.3  Buffers and Solutions  
Buffer Constituents 
Molecular biology: 
Cell Lysis buffer (P1) NaOH  
10% SDS 
H2O 
20 mM 
10 ml 
to 100 ml 
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Cell suspension buffer (P2) Glucose 
Tris 
EDTA 
H2O 
5 mM 
2.5 mM 
1 mM 
to 100 ml 
Neutralisation buffer (P 3) 3 M Potassium acetate 
Acetic acid 
H2O 
60 ml 
11.5 ml 
to 100 ml 
DNA Loading buffer (6×) Glycerin (87%) 
Bromphenol blue 
Xylene cyanol 
H2O 
3 ml 
25 mg 
25 mg 
to 10 ml 
1 M Tris-HCl  
 
TRIZMA Base 
H2O 
60.5 g 
to 500 ml 
10% SDS solution SDS 
H2O 
10 g 
to100 ml 
5 M Sodium chloride 
 
NaCl 
H2O 
580 g 
to 100 ml 
Southern Blot and colony hybridization: 
Depurination buffer HCl (1 M) 
H2O  
250 ml 
to 1L 
Denaturation buffer 
 
NaOH 
NaCl (5 M) 
H2O  
20 g 
333 ml 
to 1 L 
Neutralisation buffer 
 
Tris HCl (1 M, pH 7.4) 
NaCl 
H2O  
500 ml 
175.5 g 
to 1L 
20 × SSC 
 
NaCl 
Sodium citrate•2 H2O 
H2O  
155.3 g 
88.2 g 
to 1L 
Hybridization buffer 
 
DIG Easy Hyb Granules 
H2O  
1 bottle 
to 64 ml 
2× wash solution 20 × SSC 
10% SDS 
100 ml 
10 ml 
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H2O  to 1L 
1× wash solution 
 
20 × SSC 
10% SDS 
H2O 
50 ml 
10 ml 
to 1 L 
Maleic acid buffer Maleic acid 
NaCl 
H2O  
11.61 g 
8.8 g 
to 1L 
Blocking solution DIG blocking reagent 
Maleic acid buffer 
50 g 
to 500 ml 
Detection buffer Tris-HCl (1 M) 
NaCl 
H2O  
100 ml 
5.8g 
to 1 L 
Stripping buffer NaOH 
SDS (10%) 
H2O  
8 g 
10 ml 
to 1L 
Protein expression and in vitro assay 
10x buffer Tris-HCl 
NaCl 
MgCl2 
H2O 
750 mM 
1 M 
100 mM 
to 50 ml 
Binding buffer Tris-HCl (pH 7.8) 
NaCl 
Glycerol 
Imidazole 
H2O 
20 mM 
200 mM 
100 ml 
60 mM 
to 1L 
Borate buffer Boric acid 
H2O 
200 mM 
to 1L 
Elution buffer 
 
Tris-HCl (pH 7.8) 
NaCl 
Glycerol 
Imidazole 
H2O 
20 mM 
200 mM 
100 ml 
500 mM 
to 1 L 
Nickel solution NiSO4  100 mM 
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Stripping buffer 
 
Sodium phosphate (pH 7.4) 
NaCl 
EDTA 
H2O 
20 mM 
500 mM 
50 mM 
to 1 L 
Coomassie Brilliant Blue Brilliant Blue 250 
H2O  
Methanol 
Acetic Acid 
2 g 
450 ml 
450 ml 
100 ml 
4× Protein loading buffer Tris (1 M, pH 6.8) 
87% Glycerol 
Bromophenol blue 
SDS 
H2O  
DTT 500 mM  (The DTT is 
added directly before use.) 
5 ml 
4 ml 
10 mg 
1 g 
to 10 ml 
800 µl 
 
PBS buffer PBS tablet 
H2O 
1 tablet 
to 500 ml 
Wash buffer Tetrasodium pyrophosphate 
Perchloric acid 
H2O 
50 ml 
19.2 ml 
to 500 ml 
 
 
 
2.4   Media 
 
Table 2.4  Mediums used in the cultivation*  
Medium  Constituents pH value 
Media for E. coli cultivation 
LB medium Tryptone 
Yeast extract 
NaCl 
H2O 
10 g 
5 g 
5 g 
to 1 L 
pH 7.4 
2YT medium Tryptone 16 g pH 7.4 
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Yeast extract 
NaCl 
H2O 
10 g 
5 g 
to 1L 
Low salt LB medium Tryptone 
Yeast extract 
NaCl 
H2O 
10 g 
5 g 
2 g 
to 1 L 
pH 7.4 
Media for myxobacterial cultivation 
Trypton medium  
 
Trypton  
MgSO4
 
× 7 H2O  
H2O 
10 g  
2 g  
to 1 L 
Adjust pH to 7.2 
with KOH (10M) 
M7 medium  
 
Probion  
CaCl2 × 2 H2O  
MgSO4 × 7 H2O  
Hefe extract  
HEPES  
Starch  
Glucose 20 %  
Vitamin B12 Stock solution 
H2O 
5 g  
1 g  
1 g  
1 g  
10 g  
5 g  
10 ml  
1 ml  
to 1 L 
Adjust pH to 7.2 
with NaOH (5M). 
Glucose and VB12 
were added in after 
autoclave. 
Glucose (20%) D(+)-glucose-monohydrate  
H2O 
20 g  
100 ml 
Filter sterilize. 
VB12 stock solution  
(1 mg/10 ml) 
Vitamin B12  
H2O 
100 mg  
to 1 L 
Filter sterilize. 
M-medium Phytone Peptone 
Maltose 
CaCl2
 
× 2 H2O 
MgSO4
 
× 7 H2O  
NaFe-EDTA  
HEPES 
10 g 
10 g 
1 g 
1 g 
8 mg 
11.9 g 
Adjust pH to 7.2 
with KOH (10M). 
CTT medium Casiton 
Tris-HCl, 1M (pH 7.6) 
K2HPO4, 1M (pH 7.6)  
10 g 
10 ml 
1 ml 
Adjust pH to 7.0 
with KOH (10M). 
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MgSO4, 0.8 M 
H2O 
10 ml 
to 1 L 
PMM medium K2HPO4  
KH2PO4 
(NH4)2SO4 
Succinic acid [Na-salt]  
MgSO4
 
× 7 H2O  
H2O 
8 g 
5 g 
1 g 
6.6 g 
1.2 mM 
to 1 L 
Adjust pH to 7.0 
with KOH (10M). 
* For agar plates, 15 g/L agar was added into the medium; for soft agar plates, 7.5 g/L agar was 
added into the medium. 
 
 
 
2.5   Antibiotics 
 
Table 2.5  Antibiotics used in this work 
Antibiotic Stock solution Working concentration 
Kanamycin (Km) 50 mg/ml 30 ~ 100 µg/ml 
Ampicillin (Amp) 100 mg/ml 100 µg/ml 
Zeocin (Zeo) 100 mg/ml 15 µg/ml 
Tetracyline (Tet) 10 mg/ml 75% EtOH 5 µg/ml 
Chloramphenicol (Cm) 34 mg/ml 20 µg/ml 
Gentamycin (Genta) 20 mg/ml 6 µg/ml 
 
 
 
2.6   Instruments and materials 
• Agarose gel electrophoresis 
Electrophoresis chamber SUB-CELL® GT    (Biorad) 
Electrophoresis chamber MINI-SUB-CELL® GT  (Biorad) 
• Centrifuges 
Cool centrifugee 5805R      (Eppendorf) 
Tabletop centrifuge 5415D      (Eppendorf) 
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Centrifuge Avanti JE       (Beckmann Coulter) 
Biofuge Pico        (Heraeus) 
• Electroporator 
Gene pulser XCell       (Biorad) 
Electroporation cuvette 0.1 cm      (Biorad) 
• Electro blotter 
Trans-Blot SD Semi Dry Transfer Cell     (Biorad) 
• French Press        (SLM Aminco) 
• HPLC 
DAD-coupled HPLC       (Dionex) 
• HPLC-MS 
Agilent 110 series HPLC system     (Agilent) 
Bruker HCTplus       (Bruker) 
Bruker micrOTOF       (Bruker) 
LTQ-Orbitrap        (Thermo Finnigan) 
• Image documentation 
N-1000 Darkroom       (Peqlab) 
Camera biovision       (Peqlab) 
• Incubators 
Incubators        (Binder) 
Hybridization oven APT Line Series BFED   (Binder) 
Multitron Shakers       (Infors) 
• NMR 
Bruker Advance 500       (Bruker) 
• PCR 
Mastercycler Gradient       (Eppendorf) 
PCR Sprint Thermocycler      (Thermo Electron Corp) 
• pH-measurements 
pH-Meter 766 Calimatic      (Knick) 
• Photometer 
Helios Epsilon Spectrophotometer     (Thermo) 
• Protein purification 
Äkta Prime system       (GEHealthcare) 
• TLC 
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Alugram®SL G/UV 254 TLC Platten     (Macherey & Nagel) 
• Thermomixer 
Thermomixer compact       (Eppendorf) 
Thermomixer comfort       (Eppendorf) 
• Sterilisation 
Systec VX-150        (Systec) 
• Ultrasonic bath 
Sonarex        (Bandelin) 
• Water processing 
Milli-Q water purification system     (Millipore) 
PURELAB ultra       (ELGA) 
• Others 
Membrane filter 0.22 µm      (Millipore) 
Nylon membrane, positively charged     (Roche) 
Microspin Columns       (Amersham Pharmacia) 
 
 
 
2.7    Bacterial strains 
 
Table 2.6  Bacterial strains used in this work 
Strain Genotype/characteristics Reference 
E.coli DH10B F-mcrA∆(mrr-hdsRMS-mcrBC) 
Ø80dlacZ∆M15∆lacX74 deoR recA1 endA1 
araD 139∆ (ara,leu) 7696 galU galK rpsL 
nupG 
 
E. coli HS 996 F-mcrA∆(mrr-hdsRMS-mcrBC) 
Ø80dlacZ∆M15∆lacX74 deoR recA1 endA1 
araD 139∆ (ara,leu) 7696 galU galK rpsL 
nupG fhuA::IS 
Invitrogen 
 
E. coli SCS110 rpsL (Strr) thr leu endA thi-1 lacY galK galT 
ara tonA tsx dam dcm supE44 ∆(lac-proAB) 
[F´traD36 proAB lacIqZ∆M15] 
Stratagene 
 
E. coli BL21(DE3) F– ompT gal dcm lon hsdSB(rB– mB–) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
 
E. coli Rosetta BL21 (DE3) 
pLysS/RARE 
F- ompT hsd SB(RB– RB–) gal dcm λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) 
Novagen 
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pLysSRARE (CmR) 
 
E.coli SURE endA1 glnV44 thi-1 gyrA96 relA1 lac recB recJ 
sbcC umuC::Tn5 uvrC e14- ∆(mcrCB-
hsdSMRmrr)171 F'[proAB+ lacIq lacZ∆M15 
Tn10(tetR)] 
Stratagene 
 
E. coli GB2005 HS996 ∆recT and redα Genebridges 
E. coli GB2005-red GB2005 insertion of the pBAD recE recT γ 
recA operon 
Genebridges 
 
YZ2005 HS996 ∆recT and redα Genebridges 
A. disciform An d48 wild type  
Cystobactor sp. SBCb004 wild type  
M. xanthus DK1622 wild type  
P. putida FG2005 wild type  
  
 
 
2.8   Oligonucleotides and general plasmids 
 
Table 2.7  Oligonucleotides 
Primer Sequence (5´ 3´) 
Primers for knockout mutagenesis 
Kan_for CAGGGCGCAAGGGCTGC 
Kan_rev GGGAATAAGGGCGACACGG 
tubZ_for CGGGTCAAGCTTCAAAGAGGCT 
tubZ_rev TACGAGCTGGATCCGACTTCGAC 
Primer 1 GCTCATGAGCCCGAAGTGG 
Primer 2 CGCGCAGACCAAAACGATC 
primer A CCCTTCGGCAGCCCCAACAT 
primer B CAGCGGCAGTGGAGTGAAG 
orf1-for AGATGTAAAGCTTCGGTGGGGTC 
orf1-rev CTGCAAGAGGATCCGACATCCAG 
tubA-for GGCCTTTCAAGCTTGGACCCTGG 
tubA-rev GTCGCGCGTTGGATCCAGGGCTG 
Pat1-for GACCATCGGATCCTATGGGC 
Pat1-rev GATCGCAAGCTTGGGCCAC 
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Pat2-for CACTCGGATCCAATACAGGAG 
Pat2-rev CGTTATAAGCTTCCTAGGTAG 
patvf_for GGAGCAGGATTTGGAAGAC 
patvf_rev GACCATATGACGCTGCTG 
TubZ-exp-f GGAGCCGAATTCGTGAATGCAGTG 
TubZ-exp-r GGCGGCCGCTACGGCTGGGGC 
Cbt-Z1 GAAGTGACTCATGTTGAGCACGAGGGTG 
Cbt-Z2 GAGCGCACCAGCTCGAAGAG 
Cbt-Z3 GTCGGCGAGGGATCACTCGCGGGCTGC 
Cbt-Z4 TGCCTGAAAGAAGGGTTACCGC 
ctubA-a ACTCTGACCGACGGAGCAGGTTTTCTAC 
ctubA-b CAGCGTTGCATCCACGGTTG 
ctubA-c AATGCGCACTCCCGGTGAAAC 
ctubA-d TCGTCTGCCCGGACTACCTG 
corf1-a TGCCTGAAAGAAGGGTTACCGC 
corf1-b ATGTGGATGCTCAACCCGTAG 
corf1-c GAGCGCACCAGCTCGAAGAG 
corf1-d CATCCGAGAGGATGTGATGG 
Cbt-H1 CAACTGATCGCCCTCGAATGGGCACTC 
Cbt-H2 TGCTGCCCTGAGGCAGCAAC 
Cbt-G1 CAGGTGAAGACCGATGGCCGGCGAAAC 
Cbt-G3 CAGTTGAGACAAGTACCGCATCCTCAG 
Cbt-G4 AGATCACCTGTCCCTGCTG 
Cbt-H3 TAGTGGAGCAGGAGGTGTC 
Tn5-a GGTTTTATGGACAGCAAGCG 
Tn5-b CCCTCAGGCGACATGCGAAACGATCCTC 
ctubB-a GAGGATCGTTTCGCATGTCGCCTGAGGG 
ctubB-b GATGAGTCCCTGCAACTCG 
pTOPO-In CCTCTAGATGCATGCTCGAGC 
pTOPO-Out TTGGTACCGAGCTCGGATCC 
24P-a CGCTTGAAACCCGCACCCGCTCTACCAC 
24P-b TCGGGGAAGAGCGAGGGATC 
45M-a GGACTGAGACAAGGATCCCTACGTCGAG 
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45M-b CCGTCGGTATCCACGAGCTG 
302P-a CGAGTGAAGGCAGAACCCCTATCCCTTC 
302P-b AACTGCGCTGGATCGCGGTTC 
333P-a TCACTGACTCAAGGATCCGTTCCCCTTC 
333P-b TGCTCGAAGACGGACTCGTC 
399P-a CATCTGAGTCGTTCGCGACGTCCGGAAG 
399P-b CGCAGACCGTGTCGTCCTCCATC 
633P1-a TCCCTGATACGACCAGCTCCGGAGCTTC 
633P1-b GTCTCGGAACTTCAGCGGATCCC 
1042P-a CGGGTGATTCCCGTACATCCACGGACTC 
1042P-b GTCCGGAAGATGGTGCGACACG 
633P2-a CGCGTGACTGTCGGACCTCTTCTGG 
633P2-b ACGGGCGGTTCGCCGCGAC 
Primers for heterologous expression 
15A-Km-tub3 CAGGTGCAACGCAACGCCGCCGAGCGCGCCTCGCGGCAGCAGA
AGGCCGCCCAGCAGCGCCGGGCCCATATGAAGCGAGGATCACCC
CATGACGCGTAGGCGCTAGCGGAGTGTATACTG 
15A-Km-tub5 TGAAGTTGTACGCCTGCTCCAGTCCCCGCTCCCCGGTGAGGGAC
GCCTGCAACCGGAGATCCCTCGCGAGGAAGCGCGGCTGTTCGAA
GTCAGAAGAACTCGTCAAGAAG 
ask-tub5 CGGCCGGCCATTCCCACCACGGCGATGCCCGACAGAGACGCCTC
GTCCGCGCTACGCGTCATGGGGTGATCCTCGCTTCATATGCTAGC
TAGATTTTTGTCGAACTATTC 
ask-tub3 TTCCTCCGAACCACCGGCTCCGCCCGCGCTCGACGTCGTCCTCGC
GCCACACGCCGAAGGCGGCGTGGTCGACCGCATATGCTAGCTGA
CCTGTGAAGTGAAAAATGG 
Zeo-tub5 GCGCTCGACGTCGTCCTCGCGCCACACGCCGAAGGCGGCGTGGT
CGACCGCAGCACGTGTTGACAATTAATC 
Zeo-tub3 ATGTCGCACAATGTGCGCCATTTTTCACTTCACAGGTCAGCTAGC
ATATGTCAGTCCTGCTCCTCGGCCAC 
Tps-amp5 GTCGTTCTTCGAGCGGTAGCGTCAAGGTACTCACCGTCCAGCCC
GAGAAGGTTCCGGAACATCGAATCAC 
Tps-amp3 CCCTCATCAGTGCCAACATAGTAAGCCAGTATACACTCCGCTAG
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CATATGTGCTTCGGGGTCATTATAGC 
Genta-tub5 TCACCGAGCAACCGACATCCCCGCAGGCGACCGAGGAGGGCGA
GATTTGAAGCTTAGGCACGAACCCAGTTGACATAAG 
TetR-tub-ATG CACAGCCGCACTCCCAGCCCCGCGGCGTGCGCGAGCAATTCTCC
CGGGCTCATATAGTGCCTCTTCTCTATCACTG 
TetR-tub-TTG CACAGCCGCACTCCCAGCCCCGCGGCGTGCGCGAGCAATTCTCC
CGGGCTCAATTAGTGCCTCTTCTCTATCACTG 
H-orf2-for GTTCCTCTACAAGCGCCAGACCGACACGGCAGCCCGCGAGCGCT
CCCTCGGCAGAATAAATAAATCCTGGTGTC 
H-orf2-rev  
 
TCGGGCTGGATGTTGTACATCCGCCGCACCTCCTCGAGCGGCAG
CTCCATAAATTACGCCCCGCCCTG 
H-tubZ-for 
 
CCCACTCGGACCCGAGACACACCAAAGCAAGGGGAAGACACTC
ATGTTGAGCAGAATAAATAAATCCTGGTGTC 
H-Orf1-for  
 
TTTCAGGCAAGGGCGGTGTTGGTAAGACCACCGTCTCCGCGGCC
ACCGCCGCAGAATAAATAAATCCTGGTGTC 
H-tubA-for GTACTCGGACCGACGGAGCAGGTTTTCTACAAGGTACGGCGGCT
GCGCCCGCAGAATAAATAAATCCTGGTGTC 
H-tubA-rev GTCTCCGCGAGCACCTCGCAGGTGCGCGAGGCGATGCGCTCGGC
CAGCTCAAATTACGCCCCGCCCTG 
P450-zeo5 AGGGATTGCGGCGCGTCTCGTCGGAGAGGAAGTCCAGCATTAGT
GCCTCTTCTCTATCACTGATAGGGAGTGGTAAAATAACTCTATCA
ATGATAGAGTGTCAGTCCTGCTCCTCGGCCA 
P450-zeo3 CGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTC
CCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCT
TCTGACCTAGCTAGCCTTAAGAGCAC 
633P1-1 CCGAGGGCAAAGGAATAGATATGCTGGACTTCCTCTCCGACG 
633P1-2 CAGGACTTCAGGAAGGCGAGCAGGTCGGCGTTGACCTGATCCTT
GTGCGTGTCATGAGGAGCGTTCCCGCC 
 
 
Table 2.8  General plasmids 
Plasmids Relevant characteristics Reference 
pCR2.1-TOPO Cloning vector, lacZα, t7 , f1ori, Invitrogen 
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neoR,bla, pUC origin 
 
pGEX-6-P-1 
 
Expression vector, for expression with 
Nterminal GST Tag 
GE Healthcare 
 
pSC101-BAD-γβαA-Amp ET cloning vector Genebridges 
 
 
 
2.9   Cultivation of strains 
 
2.9.1  E. coli strain 
   All the E.coli strains were cultured in LB medium at 37°C with the appropriate antibiotics if 
necessary. Generally, 1 ml of sterile LB medium were inoculated with a few cells from a single 
colony and cultivated at 37 °C at 180 rpm overnight.  
 
2.9.2  Myxobacetria strains 
   A. discoformis An d48 was cultivated in tryptone medium for homologue growth, while 
knockout mutants were grown in the presence of kanamycin (50 µg/ml). For analysis of 
secondary metabolite production, the wild type and mutant strains were all grown in 50 ml M7 
medium.      
 
   The Cystobacter sp. SBCb004 wild type strain was cultivated in M-medium, and all mutants 
were grown in the presence of kanamycin (100 µg/ml).  
 
   Strain Myxococcus xanthus DK1622 lived in CTT medium [110]. The tubulysin producing 
mutants were grown in the presence of kanamycin (50 µg/ml). All the myxobacterial strains were 
cultivated at 30 °C and 180 rpm. 
 
2.9.3 Pseudomonas putida 
   Heterologous expression strain Pseudomonads putida FG2005 was grown in LB medium or in 
PMM medium at 30 °C (or 16 °C) and 180 rpm [71]. Kanamycin (50 µg/ml) was supplemented 
for the P. putida tubulysin-producing strains.  
 
 
 36 
 
2.10   Analysis of secondary metabolite production  
 
2.10.1  Analysis of the production from strain An d48  
   For analysis of secondary metabolite production, the An d48 wild type and mutant were grown 
in 50 ml M7 medium. 2% absorber resin Amberlite XAD-16 was added to the cultures when the 
first ball-shaped cell clumps became visible, and cultivation was continued for a further 5–7 days. 
The absorber resin and cell clumps were separated from the medium by sieving, and then 
extracted three times with 40 ml of a methanol/acetone mixture (1:1 v/v). The extracts were 
evaporated to dryness and resuspended in 0.5 ml methanol before analysis by high performance 
liquid chromatography-mass spectrometry (HPLC-MS) or using an LTQ Orbitrap Hybrid FT 
mass spectrometer.  
 
   Feeding studies of An d48 wild type and An d48-tubZ– mutant were performed in 50 ml M7 
culture, with synthetic D-/L-pipecolic acid (mono-labeled at position C4, and mono- and di-
labeled at position C5) (1 mg), d8 L-valine (2.5 mg) and d3 L-methionine (25 mg). The 
compounds were dissolved in water, sterile filtered and administered in three portions to one-day 
old cultures in three parts (100 µl every 12 h). The cells were cultivated for an additional day. 1% 
Amberlite XAD absorber resin was then added to the culture, and the cultivation was continued 
for another 5 days.  The resin and cells were processed as described previously.  
 
2.10.2  Analysis of the production from strain SBCb004  
   The SBCb004 wild type and mutant strains were grown at 30 °C for 5–7 days in 50 ml M-
medium containing 2% absorber resin Amberlite XAD-16. The resin was separated from the 
medium by sieving, and extracted with 40 ml of methanol. The extracts were evaporated to 
dryness and resuspended in 1 ml methanol before analysis by mass spectrometry.  
 
2.10.3  Analysis of the production from strain M.xanthus DK1622  
   M. xanthus strain was inoculated from an overnight culture (1:20), and cultivated at 30°C for 6 
days in 50 ml CTT medium with 50 µg/ml kanamycin, 0.7 µg/ml tetracycline, and 2% absorber 
resin Amberlite XAD-16 (added 12 hr later after tetracycline induction) [94]. The XAD resin and 
cell pellets were harvested from the medium by centrifugation, and extracted with 40 ml of an 
acetone/methanol mixture (1:3 v/v). The extracts were evaporated to dryness in vacuum and the 
residues were resuspended in 1 ml methanol before analysis by HPLC-MS.  
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   The feeding studies were performed with different amount of commercial pipecolic acid 
hydrochloride. This compound was first dissolved in 70% ethanol and administered in three 
portions to cell cultures (adding each portion per 12 hr since tetracycline induction). The cells 
was then cultivated for another 12 hr before adding the XAD absorber resin. For quantification 
experiment of strain M. xanthus::pTub-ATG, three independent colonies were carried out.  
 
2.10.4  Analysis of the production from strain P. putida  
   For P. putida, 50ml culture in PMM medium supplemented with Km (50 µg/ml) was inoculated 
from an overnight pre-culture in LB medium (1:100). After cultivation at 30oC for 2 hr with 
shaking, the culture was induced with 0.7 µg/ml tetracyclin (final concentration) for tubulysin 
production. Then it was continuously grown for 4 days at 30oC (or 1 oC). In between, 12 hr later 
after tetracycline induction, 2% absorber resin Amberlite XAD-16 was added [71]. The absorber 
resin and cell pellets were harvested from the medium by centrifugation, and extracted with 40 ml 
of an acetone/methanol mixture (1:3 v/v). The extracts were evaporated to dryness in vacuum and 
the residues were resuspended in 0.5 ml methanol before analysis by HPLC-MS.  
 
 
2.11   Chromatography and mass spectrometry 
   Standard analysis of crude extracts was performed on an HPLC-DAD system from the Agilent 
1100 series, coupled to a Brucker Daltonics HCTultra ESI-MS ion trap instrument operating in 
positive ionization mode. Compounds were separated on a Luna RP-C18 column (125 × 2 mm; 2.5 
µm particle diameter; flow rate 0.4 ml/min), with a mobile phase of water/acetonitrile each 
containing 0.1% formic acid, using a gradient from 5–95% acetonitrile over 20 min. Detection 
was by both diode array and ESI-MS.  
 
   High-resolution mass spectrometry was performed on an Accela UPLC-system coupled to a 
linear trap-FT-Orbitrap combination (LTQ-Orbitrap), operating in positive ionization mode. 
Separation was achieved using a BEH RP-C18 column (50 × 2 mm; 1.7 µm particle diameter; flow 
rate 0.6 ml/min), with a mobile phase of water/acetonitrile each containing 0.1% formic acid, 
using a gradient from 5–95% acetonitrile over 9 min. The UPLC-system was coupled to the LTQ-
Orbitrap by a Triversa Nanomate, a chip-based nano-ESI interface. In certain experiments, the 
extracts were fractionated, and single fractions were analyzed by direct infusion.  
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   The yield of tubulysin D was determined from the peak area (base peak chromatogram) by 
reference to a standard curve generated with authentic, synthetic material (a kind gift of Prof. H. 
Steinmetz). Estimates of the yields of all other metabolites were obtained by comparison of the 
peak areas to those of tubulysin D. 
 
 
2.12   Gene inactivation  
 
2.12.1  Gene manipulation in strain An d48 
   A kanamycin resistance gene was amplified from plasmid pCR 2.1-TOPO using the primer pair 
Km_for and Km_rev (Table 2.7), and the resulting fragment was cloned into vector pSUP102 to 
generate the plasmid pSUP-Km [40; 100], which was used as the inactivation plasmid in strain 
An d48.  
 
   Here, gene tubZ was taken as an example to show the inactivation steps in An d48 wild type 
strain. Primer pairs, tubZ_for and tubZ_rev (Table 2.7) were used to amplify the knockout region 
of gene tubZ from a cosmid library of A. disciformis An d48, introducing restriction sites for both 
BamHI and HindIII. The amplified fragment was cloned into vector pCR 2.1-TOPO, and 
amplification of the correct product was confirmed by restriction analysis. The fragment was then 
excised using BamHI and HindIII and sub-cloned into vector pSUP-Km, creating the inactivation 
plasmid pSUP-Km-tubZ. The inactivation vector was then electroporated into the E. coli strain 
SCS110 to enable conjugation with A. discoformis An d48. 
 
The tubZ inactivation mutant (And48-tubZ−) was generated using a modified triparental 
conjugation method [37]. An d48 wild type was cultivated at 30  oC and 170 rpm in tryptone 
medium to a cell density of 2.0 × 108–1.0 × 109 cells/ml. The cells were harvested by 
centrifugation at room temperature and resuspended in tryptone medium to a final concentration 
of 1 × 1010 cell/ml. The E. coli strains SCS110/pSUP-Km-tubZ and the helper strain 
HB101/pRK600, were cultivated at 37 oC to an OD600 0.8–1.2. The E. coli were then harvested at 
room temperature, washed 3 times and resuspended in LB medium to yield a cell density of 1 × 
1010 cells/ml. 109 cells of An d48, SCS110/pSUP-Km-tubZ and HB101/pRK600 were then 
combined. The mixture was concentrated by centrifugation and the cell pellet was resuspended in 
100 µl tryptone medium, followed by spotting onto a tryptone agar plate. The plates were then 
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incubated at 37 oC overnight. The mixed cells were scraped off the plate and resuspended in 1 ml 
tryptone medium. The resuspended cells were mixed with 3 ml of tryptone soft agar containing 
antibiotics (tryptone medium + 0.75% agar + 50 µg/ml kanamycin + 30 µg/ml gentamycin), and 
immediately plated on tryptone agar plates (tryptone medium + 1.5% agar + 50 µg/ml kanamycin 
+ 30 µg/ml gentamycin). The plates were incubated at 30 oC for 1–2 weeks until colonies became 
visible. 
 
2.12.2   Gene manipulation in strain SBCb004 
   The construction of gene knockout in SBCb004 was accomplished by homologous 
recombination in the encoding regions. Oligos were designed to amplify the knockout region in 
the middle of target gene and also introduce a stop codon. Primer pairs, Cbt-Z1 and Cbt-Z2, were 
designed to amplify the knockout region (864 bp) in the middle of target gene tubZ, and introduce 
a stop codon. The amplified DNA fragment was then cloned into pCR 2.1-TOPO vector to obtain 
the inactivation vector pTOPO-tubZ. Correct integration of plasmid pTOPO–tubZ into the 
chromosome of SBCb004 was confirmed using three different PCR reactions with primers 
pTOPO-In, pTOPO-Out, Cbt-Z3 and Cbt-Z4. Primer pair ctubA-a and ctubA-b were used to 
knockout gene tubA, while corf1-a and corf1-b were used to inactivate gene orf1 (Table 2.7).  
 
   The inactivation mutant was generated by electroporation as follows:  SBCb004 wild type cells 
were grown to an OD600 0.8–1.0, and cells were harvested from 2 ml of culture by centrifugation 
at room ttemperature. The cell pellet was then washed twice with an equal amount of washing 
buffer (5 mM HEPES (pH 7.2), 0.5 mM CaCl2), and resuspended in 50 µl ddH2O. Plasmid 
pTOPO-tubZ(tubA, orf1) (1–3 µg) was then added into the cell suspension, and the mixture was 
electroporated in a 0.1 cm cuvette (200 Ω, 25 mF, and 0.9 kV/cm). 1 ml M-medium was added to 
the cells. The suspension was transferred into a 2 ml-centrifuge tube and cultivated for 6 h at 
30 °C and 800 rpm on a thermomixer. The cells were then mixed with 1 ml M-medium, and 
plated on M-agar with 100 µg/ml kanamycin. The plates were incubated at 30 °C for 1–2 weeks 
until colonies became visible.  
 
   The insertion of Tn5 promoter into strain SBCb004 was also carried out similarly. Primer Tn5-a 
and Tn5-b were used to amplified the Tn5 promoter, while primer ctubB-a and ctubB-b were used 
to obtained the 1 kb tubB encoding region (tubB’). An overlap PCR with primer Tn5-a and 
ctubB-b was then carried out to connect both the Tn5 promoter and the tubB encoding region. 
The resulted DNA fragment Tn5-tubB’ was electroporated into SBCB004 strain subsequently. 
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When the homologous recombination happened in the tubB encoding region, the Tn5 promoter 
was directly inserted in front of the core NRPS-PKS genes of tubulysin gene cluster, and resulted 
in mutant SBCb004-Tn5. The integrations of plasmids into SBCb004 chromosome for all these 
inactivation mutants were confirmed by PCR reactions as described before, while the Tn5 
insertion mutant was verified by PCRs and sequencing.  
 
   Those identified monooxygenase genes from SBCb004 were also inactivated by the same 
method with specially designed primer pairs.  
 
 
2.13   TubZ from An d48 
 
2.13.1  Cloning, expression and purification of TubZ 
   The tubZ gene of An d48 was amplified from cosmid F5 [102] containing the Angiococcus 
disciformis An d48 tubulysin gene cluster (primer pair TubZ-exp-f and TubZ-exp-r), introducing 
flanking EcoRI and NotI sites. The resulting product was then with EcoRI and NotI, and ligated 
into pGEX-6P-1, previously digested with both EcoRI and NotI. The fidelity of the PCR reaction 
was then confirmed by sequencing. The resulting expression construct pGEX-6P-1-TubZ was 
transformed into E. coli strain BL21(DE3)pLyS. The cells were grown in LB medium (1 L) 
containing ampicillin (100 mg/ml) at 30 oC until an OD600 of 0.6–0.7 was reached, and then 
expression was induced by addition of 0.1 mM IPTG. The cultivation was continued at 16 oC 
overnight, and then the cells were harvested by centrifugation. The cell pellets were resuspended 
in ice-cold lysis buffer (25 ml; 1× PBS buffer containing 5 mM DTT and 0.5% Triton X-100) and 
lysed by French Press. The lysis solution was centrifuged (14,000 g) at 4°C for 30 min, and then 
the clarified lysate was mixed with a 50% slurry of Glutathione Sepharose 4B beads (2 ml), and 
incubated at room temperature for 30 min, with gentle agitation. The beads were then washed 
with buffer (1× PBS buffer; 10 column volumes). In the case of the GST-TubZ fusion protein, 
elution was performed directly with elution buffer (50 mM Tris.HCl (pH 8.0), 10 mM reduced 
glutathione); the protein was eluted in three fractions (10 min incubation). Discrete TubZ was 
obtained by on-column digestion of the bound GST-TubZ fusion protein. For this, 
PreScissionProtease® (5 units) was added to the beads in protease buffer, and incubated at 4 °C 
overnight. The purified proteins were flash frozen in liquid nitrogen, and stored at −80°C until 
use.  
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2.13.2   Characterization of TubZ cyclodeaminase activity 
   Assays contained TubZ–GST fusion protein (1.5 µM) or discrete TubZ protein (0.6 µM), L- or 
D-lysine (1 mM), NAD+ (100 M), and BSA (1 mg/ ml) were performed in buffer (5 mM 
Tris.HCl (pH 8)) in a total volume of 100 µl. Control incubations were performed with L- or D-
lysine in the absence of added TubZ. After 24 h of incubation at room temperature, the reactions 
were quenched by the addition of acetonitrile (200 µl). The assay mixture was chilled at −20 °C 
for at least 10 min, and then centrifuged (16060 g) at 4°C for 10 min. Derivatization was carried 
out on the assay supernatant (240 µl), using Fmoc-Cl (10 mM; 20 L) in borate buffer (10 mM; 
80 L). The reaction mixture was incubated at room temperature for 30 min, and then quenched by 
addition of 2 volumes of pure acetic acid. The same derivatization procedure was performed on a 
commercially available racemic mixture of L-/D-pipecolic acid, and enantiomerically pure D-
pipecolic acid. Following centrifugation, the supernatants were analyzed using the HPLC-DAD 
system at 25 °C. A Nucleodex-OH column (200 × 4 mm) was employed for separation with a 
solvent system consisting of H2O and acetonitrile, each containing 0.1% formic acid. The 
following gradient was applied:  30–95% acetonitrile over 35 min, at a flow rate 0.5 ml/min.   
 
 
2.14   Cloning by Red/ET recombination 
   In all the Red/ET recombination experiments, linear DNA fragments working as the 
modification cassette were obtained either by PCR or by restriction. KOD DNA polymerase was 
used to run the PCR reactions according to the manufacturer’s protocol, and the products were 
concentrated and purified by ethanol precipitation before further applications.  
 
   E.coli strain GB05-red and YZ2005 were used in the recombineering experiments [76; 111]. 
They were cultured in LB medium at 37°C with the appropriate antibiotics (kanamycin, 30 µg/ml; 
ampicillin, 100 µg/ml; gentamycin, 6 µg/ml; zeocin, 20 µg/ml; chloramphenicol, 25 µg/ml). Low 
salt LB was used to screen clones harboring Cm or Zeo resistance gene. 
 
   Generally, the GB2005-red cells harboring parent vector to be modified were inoculated by an 
overnight culture (1:40), and cultivated on a thermomixer at 37°C and 1000 rpm. When OD600 value 
reached 0.2, 0.1% L-arabinose was added into the culture to induce the recombinases expression. 
The cultivation was continued until OD600 0.4. The cells were then harvested by centrifugation, 
washed twice with ice-cold dH2O, and resuspended in 40 µl dH2O. 0.2–0.3 µg PCR product was 
mixed with the electrocompetent cells and transferred into an ice-cold electroporation cuvette (1 
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mm). The mixture was shot at 1300 V by an electroporator, followed by adding 1 ml LB medium 
immediately. It was cultivated at 37°C and 1000 rpm for 75 min before the culture were 
concentrated and spread on LB agar plates with suitable selection antibiotic. Plates were incubated 
at 37°C overnight. The selection marker located on the introduced linear DNA fragment can be used 
to select the correct transformats. Among all these Red/ET recombination reactions, all generated 
constructs were either verified by restriction analysis or confirmed by sequencing.  
 
 
2.15   Reconstitution of tubulysin biosynthetic gene cluster 
   Before stitching the tubulysin gene cluster together, the two cosmids Cos DL18 and Cos AP17 
were firstly modified by Red/ET recombination. The 5′- end tub genes on Cos DL18 were cloned 
into a minimal linear cloning vector p15A-IR-Km, flanked by a NheI site, and resulted in plasmid 
pUp. Oligonucleotides used here were 15A-Km-tub5 and 15A-Km-tub3. Two rounds of 
recombineering were used to engineer the tub genes on Cos AP17. Firstly, a minimal cloning 
vector pUC-Amp, flanked by a NheI site was designed to replace the pSuperCos backbone and the 
overlapped tubC portion on Cos AP17 with primers ask-tub5 and ask-tub3. Then, a cassette of 
zeocin resistance gene and NheI site (amplified by oligos Zeo-tub5 and Zeo-tub3) was subcloned 
onto the above plasmid, resulting in plasmid pDown. After that, the two modified vectors were 
digested by enzyme NheI. Vector pDown was cut into two fragments, and the bigger one (29 kb) 
was stitched with the linearized pUp by T4 DNA ligase. The ligated DNAs were electroporated 
into the GB05-red competent cells, and the circularized plasmids harboring the full-length tub 
gene cluster in correct direction were screened by zeocin and verified by restriction analysis.    
For expressing in heterologous expression host strain P. putida or M. xanthus, a conjugation/ 
transposition cassette IR-Tps-Amp-oriT was generated by oligos Tps-amp5 and Tps-amp3, and 
inserted into plamid p15A-Tub. Ampicillin was used to screen the correct clones. Besides, in 
order to modify the start codon of gene tubC, two parallel cassettes Genta-TetR-Ptet-TTG and 
Genta-TetR-Ptet-ATG were generated separately by primer pair Genta-tub5 and TetR-tub-TTG 
(for TTG), and primer pair Genta-tub5 and TetR-tub-ATG (for ATG). They were inserted directly 
in front of gene tubC. The resulted final clones with constructs pTub-TTG or pTub-ATG were 
selected by both Genta and Amp. Among all these Red/ET recombination reactions, all generated 
constructs were either verified by restriction analysis or confirmed by sequencing.  
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2.16    Transformation of tubulysin gene cluster into the heterologous 
expression host strains  
 
2.16.1 Electroporation of M. xanthus DK1622 
   The transformation of tubulysin gene cluster into the chromosome of M. xanthus DK1622 was 
carried out by electroporation in a 0.1 cm cuvette at 400 Ω, 25 mF, and 0.8 kV/cm. The Km-
resistant DK1622 colonies should typically appear after 6 days.  
 
2.16.2 Conjugation of P. pitida FG2005 
   The tubulysin gene cluster were integrated into the genome of P. putida FG2005 [93] by 
triparental conjugation with E. coli strain GB2005-red (containing plasmid harboring the entire 
tub gene cluster), E. coli HB101 (containing the helper plasmid pRK2013), and P. putida FG2005 
[112]. Positive clones were selected on PMM agar plates supplemented with kanamycin at 30oC. 
 
2.16.3 Verification of the plasmid integration 
   In both M.xanthus DK1622 and P.putida FG2005 strains, the successful integrations of the tub 
gene cluster into host strain chromosome were verified by two sets of colony PCRs with specially 
designed primer pairs: primer pair Cbt-A3 and Cbt-A4 located at 5′- end of tub gene cluster were 
used to amplify the tubA-orf2 region (2.4 kb); while primer pair Cbt-H3 and Cbt-G4 located at 3′- 
end of tub gene cluster were used to amplify the orf17-orf18 region (2.5 kb). 
 
 
2.17   Genetic modification of tubulysin heterologous expression system 
in E.coli 
   A serious of similar cassettes of chloramphenicol resistance gene were generated by primer 
pairs with varied homology arms. Primer orf2-for and orf2-rev were used to inactive gene orf2, 
primer tubZ-for and orf2-rev were used to delete both tubZ-orf2 genes, and primer orf1-for and 
orf2-rev were used to replace the whole operon orf1-tubZ-orf2. Primer tubA-for and tubA-rev 
were used in gene tubA deletion. These cassettes were introduced into plasmid pTub-ATG to 
replace those target genes, and the resulting deletion vectors were screened by both Cm and Amp.  
 
 
2.18   Co-expression of tubulysin gene cluster and gene 633P1 
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   Cassette Zeo-Ptet-633P1 was designed to add gene 633P1 in front of the tub gene cluster on the 
heterologous expression construct pTub-ATG. Gene 633P1 was obtained by PCR from SBCb004 
genome with primer 633P1-1 and 633P1-2, and subsequently cloned into pCR2.1-TOPO vector. 
The pTOPO-633P1 plasmid was linearized by EcoRI digestion. DNA fragment Zeo-Ptet was 
amplified by primer P450-zeo5 and P450-zeo3. Both linear DNA fragments pTOPO-633P1 and 
Zeo-Ptet were connected together by the linear to linear recombination in E.coli strain YZ2005 
[76]. The resulted plasmid pTOPO-Zeo-Ptet-633P1 was screened by zeocin. Restriction enzyme 
EcoRI was then used again to release the DNA fragment Zeo-Ptet-633P1. One step Red/ET 
recombination was carried out to insert this cassette onto the vector pTub-ATG. The resulted 
positive clones harboring plasmid pTub-633P1 were selected on low salt LB agar plates 
containing Amp and Zeo.  
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3   RESULTS AND DISCUSSION 
 
 
3.1   Discovery and annotation of the tubulysin biosynthetic gene cluster 
in Cystobacter SBCb004 
 
   Sequencing of the ca. 40 kb tubulysin gene cluster within the strain Angiococcus disciformis An 
d48 revealed that tubulysin assembly is catalyzed by a molecular ‘assembly line’, consisting of 
PKS and NRPS multienzymes, and a hybrid PKS-NRPS subunit [102]. The gene set does not 
incorporate any obvious functions for carrying out the required post-assembly line oxidation and 
acyl transfer reactions. To obtain further insights into tubulysin biosynthesis, I aimed to identify 
the gene cluster in a second myxobacterial strain, Cystobacter sp. SBCb004.  
 
   In common with Archangium gephyra Ar315, Cystobacter SBCb004 generates tubulysins A, B, 
C, G and I, incorporating tubutyrosine instead of the tubuphenylalanine of tubulysins D, E, F and 
H (Figure 1.13). To locate the tubulysin gene cluster in Cystobacter SBCb004, the SBCb004 
genome was shot-gun sequenced using 454 technology, and resulted in 276 contigs [113; 114]. 
Then, the data were analyzed by BLAST [115] using the tub genes from An d48 [102]. Finally, 
genes within an 82 kb region were functionally annotated. The SBCb004 tubulysin gene cluster 
closely resembles that in An d48. Comparison of the tubulysin biosynthetic gene clusters in 
SBCb004 and An d48 reveals a conserved architecture. By identification of the gene set common 
to both SBCb004 and An d48, the cluster boundaries was able to be defined straightforward in 
both organisms for the first time. The clusters each incorporate 11 genes, which are present in the 
same order and orientation (Figures 3.1 and Table 3.1). The core biosynthetic genes (tubB–tubF) 
encode three NRPS subunits, one PKS multienzyme, and a hybrid PKS-NRPS protein. Two 
conserved orfs (orf17 and orf18) are present downstream of gene tubF, while tubB is preceded by 
genes tubA, orf2, tubZ and orf1. Like its An d48 counterpart, no genes clearly encoding post-PKS 
tailoring functions were present in the SBCb004 tubulysin cluster.  
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Figure 3.1  Comparison of tubulysin biosynthetic gene clusters in An d48 and SBCb004. 
(A) Genetic organization of the tubulysin gene cluster in Angiococcus disciformis An d48.  Based upon the 
newly-determined cluster boundaries, gene tubG [102] was redesignated as orf25, reflecting the fact that it 
is not part of the tubulysin pathway.  
(B) Genetic organization of the tubulysin gene cluster in Cystobacter sp. SBCb004.   
(C) Genetic organization of the tubulysin gene cluster fragment in Stigmatella aurantiaca DW 4/3-1.  
(D) Model for tubulysin biosynthesis, showing the domain organization of the PKS-NRPS assembly line 
and the structures of the chain extension intermediates. The structures of the known tubulysins are shown, 
as well as that of the intermediate structure pretubulysin A and D. 
 
 
   Gene orf1 is predicted to encode an anion-transporting ATPase, while the orf2 gene product 
exhibits similarity to hypothetical proteins. Mutual sequence homology between the SBCb004 
and An d48 homologues is high (Orf1: 78% identity/90% similarity; Orf2: 69% identity/82% 
similarity vs. 68–73% identity/78–81% similarity for the PKS/NRPS proteins) which suggests 
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evolutionary pressure to maintain their functions. However, neither protein has an obvious role to 
play in tubulysin biosynthesis.   
 
Table 3.1  Proteins encoded in the sequenced region in the SBCb004 tubulysin biosynthetic gene 
cluster and their putative functionsa 
NRPS/PKS portion of the gene cluster 
Protein aa Proposed function 
(Protein domains with their position in the sequence)b 
TubB   1520 NRPS domains: C (62−493), A (494−1416), N-MT (971−1368), PCP (1432−1500) 
TubC 2628 NRPS domains: C (77−515), A (516−1027), PCP (1044−1112), C (1136−1569), A 
(1570−2499), N-MT (2042−2451), PCP (2514−2582) 
TubD 3511 PKS domains: KS (11−441), AT (527−852), KR (939−1370), DH (1371−1652), ER 
(1678−1980), ACP (2062−2157) 
NRPS domains: HC (2190−2624), A (2625−3138), PCP (3153−3223), Ox (3231−3509) 
TubE 1161 NRPS domains: C (47−482), A (483−1034), PCP (1051−1121) 
TubF 2843 PKS domains: KS (5−436), AT (522−847), KR (925−1721), C-MT (1309−1540), DH 
(1722−1997), ER (2023−2322), ACP (2404−2506), TE (2541−2815) 
ORFs encoded upstream and downstream of tubB–tubF 
Protein aa Proposed function of the 
homologous protein 
Source of the 
homologous protein 
Similarity/ 
identity 
GenBank 
accession no.  
OrfC 735 Outer membrane protein, OMP85 
family, putative 
Stigmatella aurantiaca  71%/57% EAU64371.1 
OrfB 1549 Hypothetical protein 
MXAN_6465 
Myxococcus xanthus  65%/48% ABF91418.1 
OrfA 273 α/β hydrolase fold Geobacter uraniireducens 91%/81% ABQ27606.1 
TubA 432 TubA  Stigmatella aurantiaca  89%/81% EAU66910.1 
Orf2 219 Conserved hypothetical protein  Stigmatella aurantiaca  86%/74% EAU66945.1 
TubZ 386 TubZ  Stigmatella aurantiaca  91%/86% EAU66930.1 
Orf1 394 Hypothetical protein (Orf1) Angiococcus disciformis 90%/78% CAF05646.1 
Orf17 337 Patatin-like protein (Orf18) Angiococcus disciformis 77%/62% CAF05653.1 
Orf18 368 Patatin-like protein  (Orf18) Angiococcus disciformis 82%/68% CAF05653.1 
OrfD 124 Chloroplast heat shock protein 70  Pennisetum glaucum 50%/33% ABP65327.1 
OrfE 119 ChpK Stigmatella aurantiaca  93%/89% EAU64035.1 
OrfF 271 Protein kinase  Stigmatella aurantiaca  49%/33% EAU63389.1 
aFor the corresponding proteins in the A. disciformis An d48 gene cluster, please see [102]. 
bDomain boundaries were assigned, when possible, based on the solved structures of the individual 
domains. 
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The product of gene tubA shows similarity to NRPS C domains [102]. Notably, a sequence 
(DHxxxDx) within core motif C3 is closely similar to a proposed signature sequence (HHxxxDG) 
for enzymes which effect acyl transfer, such as chloramphenicol acyltransferase and 
dihyrolipoamide acyltransferase [116]. Thus, TubA may serve as one of the missing acyl 
transferases in the tubulysin pathway. In support of a shared role for the TubA proteins in the two 
strains, the SBCb004 and An d48 homologues show a high degree of sequence conservation (56% 
identity/73% similarity). However, the proposed functions remain to be directly demonstrated.  
 
orf17 and orf18 both encode patatin-like proteins, which show high mutual sequence 
homology (60% identity/70% similarity in the case of the SBCb004 proteins), suggesting 
evolution by gene duplication. Interestingly, the closest homologue to both Orf17 and Orf18 in 
SBCb004 is Orf18 of An d48, which may imply that orf17 of An d48 has diverged from the other 
sequences. Patatin-like proteins exhibit lipid acyl hydrolase activity [117; 118], a function 
apparently not required in the tubulysin pathway. Intriguingly, however, genes encoding patatin-
like proteins are also present in the DKxanthene gene clusters of the myxobacteria Myxococcus 
xanthus DK1622 and Stigmatella aurantiaca DW4/3-1 [47], suggesting that the enzymes may 
play a previously unsuspected role in natural product biosynthesis.   
 
Predictably from the defined boundaries, orfs upstream of tubA and downstream of orf18 in 
both organisms have no obvious function in the tubulysin pathway. Thus, the oxidase activities, 
and possibly a second acyl transferase enzyme in addition to TubA, are apparently lacking in both 
clusters, and so are presumed to be located elsewhere in the genome. Such split cluster 
PKS/NRPS architecture is unusual for Streptomyces, but has precedent in the myxobacteria [119-
121]. The fact that this split organization is conserved in two different species argues for the 
presence of the tubulysin genes in an ancestor common to both Cystobacter SBCb004 and 
Angiococcus An d48 – that is, that the cluster evolved into its present form prior to the speciation 
event within the Cystobacterineae suborder. Phylogenetic analysis based on 16S rDNA supports 
this hypothesis, as An d48 and SBCb004 belong to the same family, sharing membership with 
another potential tubulysin producing-strain Archangium gephyra Ar g1 (Figure 3.2). 
 
Analysis by BLAST also revealed a portion of the tubulysin gene cluster comprising tubA, orf2, 
tubZ, and fragments of orf1 and tubF, in the publically-available genome of a third myxobacterial 
strain, Stigmatella aurantiaca DW 4/3-1 (Figure 3.1C). This architecture may have arisen from 
 49 
 
deletion of the intervening genes (tubB–tubE) from an ancestral cluster. Interestingly, the 
Cystobacter TubA, Orf2 and TubZ proteins show higher sequence identity to their Stigmatella 
homologues than to those of Angiococcus (Table 3.1), despite the closer evolutionary relationship 
between Cystobacter and Angiococcus (as judged on the basis of 16S rDNA) (Figure 3.2). 
Consistent with the fact that only part of the gene cluster is present in S. aurantiaca, the strain is 
not known to produce any of the tubulysins. 
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3.2   Characterization of gene tubZ and the stereochemistry of the 
pipecolic acid starter unit in the tubulysin pathway  
 
Although the tubulysin biosynthetic gene cluster does not incorporate any obvious function for 
carrying out the required post-assembly line oxidation and acyl transfer reactions, I identified a 
gene encoding a lysine cyclodeaminase (tubZ), whose protein product is likely to be involved in 
the biosynthesis of the unusual amino acid pipecolate, the presumed starter unit for tubulysin 
assembly [122; 123]. To demonstrate directly the involvement of tubZ in the pathway, gene 
inactivation by insertional mutagenesis in both An d48 and SBCb004 strain as well as TubZ 
protein expression and in vitro assay were carried out. 
 
 
3.2.1  Inactivation of tubZ in An d48 
   The gene tubZ was knocked out form strain An d48 by homologous recombination. The 
plasmid pSUP-Km was designed and generated as the inactivation vector, and triparental 
conjugation was used to transform the inactivation plasmid pSUP-Km-tubZ into strain An d48. 
Integration of plasmid pSUP-Km-tubZ into An d48 chromosome was demonstrated by three 
different PCR reactions, using the genomic DNA of An d48 wild type and five exconjugants as 
templates (Figure 3.3). For these PCR reactions, one set of primers (primers 1 and 2) was 
designed to bind to the backbone of vector pSUP-Km-tubZ.  The other set of primers (A and B) 
was designed to bind to the genomic DNA adjacent to the expected insertion site (Table 2.7). In 
the An d48-tubZ− knockout mutants, PCR using primers 1 and A or primers 2 and B, yielded 
products of 1.29 kb and 2.0 kb, respectively, consistent with the integration of the knockout 
plasmid at the expected location (Figure 3.3). In contrast, PCR of the wild type strain using 
primers 1 or 2 did not yield product, as predicted, due to the absenced of a primer binding site in 
the genomic DNA. However, a control reaction on the wild type employing primers A and B 
resulted in the expected band of 2.26 kb, while no product was obtained with this primer 
combination from the mutant (the product would be 10 kb in length, too long for amplification 
under the conditions used). Taken together, the PCRs clearly demonstrate that all five analyzed 
And48-tubZ− mutants contained the expected knockout in tubZ.    
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Figure 3.3  Confirmation of the inactivation of tubZ in An d48 by PCR.   
(A) Genetic organization of chromosomal DNA in Angiococcus disciformis wild type.   
(B) Genetic organization of chromosomal DNA in mutant An d48-tubZ–.  From right to left: tubZ truncated 
at the 3′-end (tubZ′), pSUP-Km vector backbone, tubZ truncated at the 5′-end (tubZ″). 
(C) PCR reaction with primers 1 and A, yielding a product of 1.29 kb from the mutants.   
(D) PCR reaction with primers 2 and B, yielding a product of 2.0 kb from the mutants.   
(E) PCR reaction with primers A and B.  Only the wild type produces a product (2.26 kb).  In the figure, 
the designation ‘WT’ represents the wild type of An d48, and ‘Mutants’ represents five distinct And48-
tubZ− exconjugants. 
 
 
   As this mutation was expected to interrupt the supply of pipecolic acid, it was anticipated that 
the resulting strain would no longer produce tubulysins. To our surprise, analysis by HPLC-MS 
revealed tubulysin D in extracts of the mutant An d48-tubZ– at approximately 3% of wild type 
levels, but in addition, substantial amounts of a novel metabolite (m/z = 670.4 Da); tubulysins E, 
F and H were not detected. This result strongly implicates TubZ in provision of the pipecolic acid 
moiety, but suggests there is a second lysine cyclodeaminase function in A. disciformis.  
 
   The relationship of metabolite 670.4 to the tubulysins was first confirmed by supplementation 
of culture broths with commercially-available d8 L-valine, yielding an incorporation pattern 
analogous to that of tubulysin D (Figure 3.4). Accurate mass determination on compound 670.4 
using a Thermo LTQ Orbitrap Hybrid FT mass spectrometer gave a value of 670.399 Da, 
consistent with a molecular formula of C36H55N5O5S (calculated [M+H]+= 670.400 Da, ∆= –0.939 
ppm). As the metabolite appeared to have the structure of the proposed first enzyme-free 
intermediate in the pathway – that is, the polyketide-nonribosomal polypeptide core minus the 
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four post-assembly line oxidative and acylation reactions – designating it as ‘pretubulysin D’. 
Furthermore, reanalysis of extracts of wild type A. disciformis An d48 revealed low levels of 
pretublysin D (Figure 3.5A and B), supporting its intermediacy in the pathway. Therefore, it was 
reasoned that pretubulysin might represent a stable analogue of the more complex tubulysins, and 
would thus be well suited for evaluation as a drug candidate. 
 
 
 
Figure 3.4  Feeding of d8 L-valine into mutant An d48-tubZ–.  
(A) HPLC-MS analysis of compound 670.4, none feeding control sample. 
(B) HPLC-MS analysis of compound 670.4, feeding with d8 L-valine.  
 
 
I aimed to prove the structure of pretublysin D by NMR. However, despite growth of A. 
disciformis on a 20 L scale, it was unable to purify sufficient quantities of of the compound. I 
therefore used tandem mass spectrometry (MS2–MS6) to probe the structure, and compared the 
fragmentation pattern to that of tubulysin D (the MS2 data are presented in Figure 3.5C and D). 
The patterns showed little similarity, suggesting that the presence of the acyl groups in tubulysin 
D significantly influenced the mode of fragmentation. Nonetheless, accurate mass analysis of 
pretubulysin D fragments revealed molecular formulae consistent with the proposed structure.  
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Figure 3.5  Identification of pretubulysin D.  
(A) HPLC-MS analysis (base peak chromatogram (BPC)) of mutant An d48-tubZ– . Peaks corresponding to 
tubulysin D (1) and pretubulysin D (5) are indicated.  
(B) HPLC-MS analysis (BPC) of extracts of wild type A. disciformis An d48, showing peaks corresponding 
to 1 and 5.  
(C) Comparative analysis of the MS2 fragmentation patterns of 1. 
(D) Comparative analysis of the MS2 fragmentation patterns of 5. Comparable fragments lost from each 
metabolite are indicated using the same color. The mass spectra include the retention time and molecular 
mass of the respective parent ions, as well as colored labels to indicate the fragments lost to generate each 
daughter peak. All data were obtained on a Thermo LTQ Orbitrap Hybrid FT mass spectrometer. 
 
 
Luckly, our cooperators in Prof. Kazmaier`s group succeeded to synthesize the compound 
pretubulysin D [124; 125]. To provide final proof for this biosynthetic hypothesis and to 
investigate the biological activity of pretubulysin in more detail, this synthesized standard 
compound was used as a comparison template. All mass spectrometric data (MS2–MS6) obtained 
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on the biosynthetic material were essentially identical to those from analysis of authentic, 
synthetic pretubulysin, confirming the compound’s identity (data now shown).  
 
 
3.2.2  Inactivation of tubZ in SBCb004 
   In order to confirm the function of tubZ in strain SBCb004, a similar inactivation mutant was 
also generated in this strain. A compound with a mass (m/z 686.4 [M+H]+) consistent with 
pretubulysin A was identified in extracts of the Cystobacter sp. SBCb004 wild type strain, at 42% 
yield relative to tubulysin A. As the An d48-tubZ– mutant produced increased amounts of 
pretubulysin D relative to wild type A. disciformis [126], I hope to boost the titer of pretubulysin 
A in SBCb004 by engineering the equivalent tubZ mutation. HPLC-MS analysis of the resulting 
mutant, SBCb004-tubZ–, revealed that the strain accumulated pretubulysin A at approximately 5-
fold wild type levels, whereas the production of tubulysin A was decreased by 20-fold (Figure 
3.6).  
 
   The availability of the genome sequence of SBCb004 allowed it possible to probe for the 
presence of additional lysine cyclodeaminases in the strain which could complement the 
inactivated TubZ. BLAST analysis revealed two genes with homology to ornithine 
cyclodeaminases (20% and 25% sequence identity to TubZ) (Table 3.2). As RapL exhibits 
ornithine cyclodeaminase activity as a side reaction [123], it seems reasonable that the detected 
ornithine cyclodeaminases may catalyze low levels of lysine cyclodeamination, explaining the 
continued presence of pipecolic acid in the SBCb004-tubZ– mutant. Given the evolutionary 
relationship between Cystobacter SBCb004 and Angiococcus disciformis An d48, it is likely that 
An d48 harbors homologues of these two genes. 
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Figure 3.6  Production of tubulysin A (6) and pretubulysin A (11) by SBCb004 wild type and mutant 
SBCb004-tubZ–. 
(A) HPLC-MS analysis (base peak chromatogram (BPC)) of wild type SBCb004. Peaks corresponding to 
tubulysin A (6) and pretubulysin A (11) are indicated. 
(B) HPLC-MS analysis (BPC) of extracts of mutant SBCb004-tubZ–. Peaks corresponding to tubulysin A 
(6) and pretubulysin A (11) are indicated. 
 
 
Table 3.2  The cyclodeaminases annotated in the genome of SBCb004. 
Protein aa Proposed function of the 
homologous protein 
Source of the 
homologous protein 
Similarity/ 
identity 
GenBank 
accession no. 
TubZ 386 TubZ protein  
 
Stigmatella aurantiaca 
DW4/3-1 
91% / 86% ZP_01462307.1 
Contig 124-Orn 
 
320 ornithine cyclodeaminase 
/mu-crystallin family protein  
Myxococcus  
xanthus DK 1622 
81% / 70% YP_635171.1 
Contig 256-Orn  346 ornithine cyclodeaminase/ 
mu-crystallin 
Methylobacterium 
nodulans ORS 2060 
49% / 33% YP_002501996.
1 
 
 
   In addition, although analysis by mass spectrometry of pretubulysin D from An d48 strongly 
supported its proposed structure, it is also necessary to obtain sufficient quantities of the 
pretubulysin compound to allow structural proof by NMR. SBCb004-tubZ– mutant was then 
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grown on large scale in the presence of XAD adsorber resin to generate enough pretubulysin A. 
Later, it was isolated and analyzed by NMR by Dominik Pistorius [127]. The final structure 
elucidation result strongly supports the proposed structure for pretubulysin A. 
 
 
3.2.3  Stereochemistry investigation of the starter unit pipecolic acid 
   The final configuration of the N-methyl pipecolic acid in the tubulysins is D [100], therefore it 
was hypothesized that free D-pipecolic acid (either generated directly by the cyclodeaminase 
TubZ, or by epimerization of an initially-formed L-isomer), might be selected as a substrate by 
the tubulysin PKS-NRPS. Interestingly, the lysine cyclodeaminases RapL from the rapamycin 
pathway (40% identity/53% similarity to TubZ) and Pip from friulimicin biosynthesis (45% 
identity/56% similarity to TubZ), have been shown to generate exclusively L-pipecolic acid from 
L-lysine [122; 123; 128]. To address the stereospecificity of TubZ, the An d48 enzyme was 
expressed in recombinant form as a C-terminal translational fusion with glutathione-S-transferase 
(GST), and confirmed the identity of the protein by matrix assisted laser desorption ionization-
time-of-flight mass spectrometry (MALDI-TOF-MS) analysis.  
 
   TubZ was purified as its GST fusion, and also as a discrete protein by on-column cleavage of 
GST using PreScission Protease® (Figure 3.7A). The recombinant TubZ proteins (GST-TubZ or 
TubZ) were then incubated with either L- or D-lysine, NAD+ and BSA at 30 °C for 24 h [123]. 
The reactions were quenched by the addition of acetonitrile. Prior to analysis by HPLC-MS, the 
assay mixtures were derivatized with 9-fluorenylmethyl chloroformate (Fmoc-Cl). Crucially, I 
was able to separate Fmoc-derivatized, commercially-available L- and D-pipecolic acid from each 
other by chiral chromatography (Figures 3.7B and C). Assays with the lysine substrates and GST-
TubZ or discrete TubZ gave identical results. In each case, analysis of the assay containing D-
lysine did not reveal any evidence for formation of the product pipecolic acid (Figure 3.7D), 
relative to controls performed with L-/D-lysine in the absence of TubZ (Figure 3.7G). In contrast, 
pipecolic acid was detected in the assays with L-lysine (Figure 3.7E), and was shown to be 
exclusively the L-isomer by spiking the assay mixture with authentic, derivatized D-pipecolic acid 
(Figure 3.7F). Thus, TubZ shows the same substrate and product stereospecificities as RapL and 
Pip. 
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Figure 3.7 Characterization of TubZ cyclodeaminase activity. 
(A)  SDS-PAGE analysis of GST-TubZ (lane 1) and discrete TubZ (lane 3). Lane 2 contains molecular 
weight markers, with the indicated masses. The calculated molecular weight of GST-TubZ is 67.698 kDa, 
while that of TubZ is 40.501 kDa. 
(B)  Chiral HPLC-MS analysis (extracted ion chromatogram (EIC), m/z [M+H]+ = 352.2) of a 1:1 mixture 
of Fmoc-derivatized, commercially-available L- and D-pipecolic acid. Peak identities were assigned by 
comparison to analysis of Fmoc-derivatized D-pipecolic acid alone. Inset is the mass spectrum of Fmoc-
derivatized L-pipecolic acid (calculated m/z [M+H]+ = 352.16). 
(C)  Chiral HPLC-MS (EIC) analysis of the Fmoc-derivatized commercially-available D-pipecolic acid 
alone.  
(D)  Chiral HPLC-MS (EIC) analysis of the TubZ reaction carried out in the presence of D-lysine. 
(E)  Chiral HPLC-MS (EIC) analysis of the TubZ reaction carried out in the presence of L-lysine. 
(F)  Mixture of the assay shown in (E) and Fmoc-derivatized D-pipecolic acid (C). 
(G)  Chiral HPLC-MS (EIC) analysis of a representative negative control reaction carried out with L-lysine 
in the absence of TubZ. 
 
 
At this stage, it remained a possibility that the L-pipecolic acid generated by TubZ was 
epimerized to the D-isomer before activation by TubB by an as yet unidentified epimerase. To 
probe this question directly, I used the synthesized two enantiomers of pipecolic acid in 4,5-di-
deuterium-labeled form (synthesized by Prof. Kazmaier`s laboratory) [126] as feeding substrates. 
The enantiomerically pure materials were administered to cultures of both wild type An d48 and 
the An d48-tubZ–  mutant [126]. Analysis by HPLC-MS (Figure 3.8) showed that only the L-
isomer of pipecolate was incorporated in either case, strongly suggesting that epimerization 
occurs following attachment of the amino acid to the multienzyme although module TubB lacks a 
classical epimerization (E) domain [129; 130] to generate the required stereochemistry.  
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Figure 3.8  Feeding studies with deuterium-labeled L-pipecolic acid.  
Peak of tubulysin D. 
(A) Absence of supplementation with pipecolic acid.   
(B) Supplementation with di-deuterium labeled L-pipecolic acid.   
(C) Supplementation with di-deuterium labeled D-pipecolic acid.   
 
 
Further support for the lack of epimerization by TubB comes from phylogenetic analysis of the 
TubC condensation domain which accepts the N-methyl pipecolic acid as substrate: the C domain 
clusters together with other C domains with demonstrated specificity for L-amino acids at both 
their donor and acceptor sites (so-called LCL domains) [131] (Figure 3.9). This analysis also 
argues against the possibility that the TubC C domain functions as a condensase/epimerase [132], 
a dual-function domain which has been shown in other NRPS pathways to convert L-amino acids 
to their D-isomers. Thus, epimerization apparently occurs downstream of the first round of chain 
extension and is likely to be catalyzed by an external racemase [133]. Intriguingly, only the PCP 
domain of TubD incorporates a sequence motif at the phosphopantetheine attachment site 
(GXDSX) which resembles the GGDSI motif previously implicated in recognition between E and 
PCP domains in cis [134], perhaps indicating that the epimerization in trans may occur at this 
stage of chain extension. However, further studies will be required to elucidate the precise timing 
of this cryptic reaction. 
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Figure 3.9  Phylogenetic analysis of the C domains of TubB and TubC. 
The tree includes representative members of the three known types of C domains [131]: LCL, which are 
specific for L-amino acids at both their donor and acceptor sites; DCL, which accept D- amino acids at their 
donor sites, and L-amino acids at their acceptor sites; and Dual, C domains which show dual condensation 
and L-to-D epimerization activity.  Branch length indicates the number of inferred amino acid changes per 
position.  Abbreviations:  Arf, arthrofactin; Syp, syringopeptin; Srf, surfactin; Tyc, tyrocidine.  In each case 
the module from which the sequence derives is indicated. 
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3.3  Discovery of 22 natural tubulysins from Angiococcus disciformis  
An d48 and Cystobacter sp. SBCb004 
 
   The presence of the pretubulysins in the wild type strains prompted me to re-analyze the 
extracts for additional metabolites, which may have escaped detection in earlier experiments. I 
further found using a combination of feeding studies and high-resolution tandem mass 
spectrometry, that SBCb004 and An d48 together biosynthesize 22 additional tubulysin 
derivatives. 
 
   I found 11 further candidates for novel compounds in A. disciformis An d48, with molecular 
masses m/z [M+H]+ = 628.4, 656.4, 670.4 (different retention time than that of pretubulysin D), 
672.4, 686.4 (×2), 700.4, 714.4, 744.4, 772.4, and 786.4 (Figure 3.10). Although most of these 
metabolites appeared to be minor in comparison to tubulysin D (see Figure 3.10 for yield 
estimates), compound 670.4 was present in significant amounts (as judged by relative peak area 
in the HPLC-MS chromatogram). In each case, a likely relationship to the tubulysins was 
established by feeding deuterium-labeled L-pipecolic acid, valine, or both and by comparison of 
the incorporation pattern to that of pretubulysin D (5). In Figure 3.11, the compound 14 (mass 
670.4 but different retention time than that of pretubulysin D) was shown here as an example of 
the feeding study. Comparison of the fragmentation patterns of metabolites 772.4 and 786.4 to 
those of the tubulysins D–F and H (Figure 3.13), allowed me to assign the structures to desacetyl 
tubulysin E (12) and desacetyl tubulysin D (13), respectively (Figure 3.10). Although 
biosynthetic considerations (i.e. the defined stereospecificities of adenylation (A) and C-
methyltransferase domains) strongly suggest that the stereochemistry of these metabolites should 
be shared with the parent compounds, I cannot make any definitive statements on this issue in the 
absence of NMR data.  
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Figure 3.10  Novel tubulysins produced by A. disciformis An d48.  
HPLC-MS analysis (BPC) of wild type extracts. Peaks corresponding to the five known (1–5) (Figure 1.13) 
and eleven novel tubulysins (12–22) are indicated.   
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Feeding experiment proved that compound (14) belongs to the tubulysin family (Figure 3.11). 
Based on its accurate mass, the most probable molecular formula of compound 670.4 (14) was 
C35H51N5O6S. It differs from pretubulysin D by –CH4 and +O, demonstrating that this new 
compound is not simply a stereoisomer of pretubulysin D. It was hypothesized that the metabolite 
might have lost a methyl group relative to pretubulysin D (accounting for –CH2), and that it 
would incorporate an extra oxygen (+O) and a site of unsaturation (–2H) (e.g., a carbonyl 
functionality) (Figure 3.12). Subsequently, this hypothesis was confirmed by feeding experiment 
of d3-methionine and NMR analysis (done by Dominik Pistorius) [127]. 
 
 
Figure 3.11  Feeding studies of compound (14) (mass 670.4) with deuterium-labeled L-pipecolic acid 
and d8 valine. The detailed data for all the other compounds were shown in reference [127].  
(A) Absence of supplementation with pipecolic acid.   
(B) Supplementation with di-deuterium labeled L-pipecolic acid.   
(C) Absence of supplementation with valine.   
(D) Supplementation with deuterium-labeled (d8) valine.   
The analyses shown in (A) and (B) were carried out on a Thermo LTQ Orbitrap Hybrid FT mass 
spectrometer, while analyses (C) and (D) were performed on an Agilent 1100 series HPLC-MS.  
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Figure 3.12  Detailed analysis of the MS2 fragmentation patterns of the novel tubulysins from An d48. 
Compound (14) was taken here as an example. Shown are the proposed structure of the metabolite and all 
fragments, the molecular formulae and calculated molecular masses of the fragments, and the 
experimentally-determined molecular mass. Masses shown are typically for the predicted protonated 
species, but no claim is being made as to the location of the charge on the fragments. Data were obtained 
on a Thermo LTQ Orbitrap Hybrid FT mass spectrometer. The detailed data for all the other compounds 
(10-22) were shown in the reference [127]. 
 
 
With this structure in hand, it was possible to assign compounds 656.4 and 672.4, to N-
desmethyl pretubulysin analogues in which the C12 carbonyl group had alternately been reduced 
to a hydroxyl (672.4; N-desmethyl 12-hydroxy pretubulysin D (15)), or to a methylene 
functionality (656.4; N-desmethyl pretubulysin D (16)); in the case of compound 15, however, I 
cannot rule out the alternative that the hydroxyl group is instead located at the adjacent C11 
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position, consistent with post-assembly line hydroxylation of metabolite 16. In any case, a 
compound corresponding to the intermediate dehydrated analogue was not detected. In addition, 
one of the two compounds with mass m/z [M+H]+ = 686.4 (17) appears to be the 11-hydroxy 
version of metabolite 14. By MS analysis, it was also possible to putatively identify compound 
714.4 as N-desmethyl 11-acetoxy pretubulysin D (18), referred to in earlier synthesis literature as 
tubulysin U [108; 135; 136], demonstrating that at least two of the normal post-assembly line 
modifications can occur even in the absence of N-methylation. By similar logic, the second peak 
at 686.4 was attributed to N-hydroxymethyl pretubulysin (19) and that at 744.4 to its 11-acetoxy 
analogue (20). Analysis of the compound 700.4 revealed fragments consistent with the presence 
of an N-hydroxymethyl functionality and a 12-keto group, leading to its identification as N-
hydroxymethyl 12-keto pretubulysin D (21). Finally, metabolite 628.4 appears to comprise a 
truncated pretubulysin derivative in which tubuphenylalanine has been replaced by phenylalanine 
(22).  
 
I next analyzed extracts of wild type SBCb004 for the corresponding novel tubulysins, using 
the same analytical methodology. This comparison revealed a tubutyrosine analogue for each of 
the new compounds (compounds 23–33) (Figure 3.14, Table 3.3). As with the tubulysin D series, 
the amounts of these compounds relative to tubulysin A were uniformly low; however the 
specific yield profiles for the various analogs differ between the strains. 
 
Although the amounts of the new metabolites (Table 3.3) enabled “structure elucidation” by 
mass spectrometry, the yields were insufficient to allow full structure proof by NMR, or 
evaluation of cytotoxicity relative to the parent compounds. Nonetheless, the high resolution MS 
analysis of the parent ions and all fragments is fully consistent with the suggested structures, there 
is strong internal concordance among the proposed fragmentation patterns (Figure 3.13), and the 
structural assignments are in complete agreement with the feeding studies. In addition, the mode 
of biosynthesis significantly restricts the number of possible structures (including stereochemistry) 
that can result from the tubulysin pathway. Importantly, in every case, the proposed structures can 
be rationalized in terms of reasonable variations in the action of a specific domain or domains 
within the assembly lines.  
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Figure 3.13  Comparative analysis of the MS2 fragmentation patterns of the tubulysins from A. 
disciformis An d48. 
Comparable fragments lost from each metabolite are indicated using the same color. The mass spectra 
include the retention time and molecular mass of the respective parent ions, as well as colored labels to 
indicate the fragments lost to generate each daughter peak. All data were obtained on a Thermo LTQ 
Orbitrap Hybrid FT mass spectrometer. 
 
 
Table 3.3  Novel metabolites identified in strains An d48 and SBCb004. 
Metabolites in strain An d48 Metabolites in strain SBCb004 
No
. 
Compound name Mass 
[M+H]+ 
No
. 
Compound name Mass   
[M+H]+ 
 5 Pretubulysin D 670.40 11 Pretubulysin A 686.39 
12 Desacetyl tubulysin E 772.43 23 Desacetyl tubulysin B (Tubulysin W) 788.43 
13 Desacetyl tubulysin D 786.45 24 Desacetyl tubulysin A 802.44 
14 N-desmethyl 12-keto pretubulysin D 670.36 25 N-desmethyl 12-keto pretubulysin A 686.36 
15 N-desmethyl 12-hydroxy pretubulysin D 672.38 26 N-desmethyl 12-hydroxy pretubulysin A 688.37 
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16 N-desmethyl pretubulysin D 656.38 27 N-desmethyl pretubulysin A 672.38 
17 N-desmethyl 11-hydroxy, 12-keto 
pretubulysin D 
686.36 28 N-desmethyl 11-hydroxy, 12-keto  
pretubulysin A 
702.35 
18 N-desmethyl 11-acetoxy pretubuylysin D 
(Tubulysin U) 
714.39 29 N-desmethyl 11-acetoxy pretubuylysin A 
(Tubulysin X) 
730.39 
19 N-hydroxymethyl pretubulysin D 686.39 30 N-hydroxymethyl pretubulysin A 702.39 
20 N-hydroxymethyl 11-acetoxy 
pretubulysin D 
744.40 31 N-hydroxymethyl 11-acetoxy pretubulysin 
A 
760.39 
21 N-hydroxymethyl 12-keto pretubulysin D 700.37 32 N-hydroxymethyl 12-keto pretubulysin A 716.37 
22 Phenylalanine pretubulysin D 628.35 33 Tyrosine pretubulysin A 644.35 
 
 
 
Figure 3.14  Proposed structures of the novel tubulysins identified in Cystobacter sp. CBSb004. 
 
 
   In summary, the analysis of the molecular basis for this diversity-oriented biosynthesis provides 
new insights into the function of PKS and NRPS natural product ‘assembly lines’. It was also 
showedn that pretubulysin D retains much of the potency of its more structurally elaborate 
relatives (see paper). Thus, the 22 additional simplified analogues are attractive targets for 
chemical synthesis, with the aim of deepening our understanding of structure-activity 
relationships within the tubulysin family of compounds.  
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3.4   Genetic modification of tubulysin biosynthetic genes in natural 
producer strains 
 
   As noted earlier, the conserved tubulysin biosynthetic gene cluster in both An d48 and 
SBCb004 strains contains several open reading frames whose functions have been unclear to date. 
These include the genes tubA, orf2, and orf1 at the 5′ end of the gene set. The observation that 
they share a high degree of mutual sequence homology (56–78% identity/73–90% similarity) 
[127] suggests that they play a role in the biosynthesis. Based on the sequence analysis, TubA 
was early supposed to serve as one of the missing acyl tranferases in the tubuysin biosynthesis 
process [102]. However, neither orf1 (predicted to encode an anion transporting ATPase) nor orf2 
(similar to hypothetical proteins only) has an obvious role to play in tubulysin biosynthesis.  
 
   Both orf17 and orf18 encode patatin-like proteins, which show high mutual sequence homology 
(60% identity/70% similarity in the case of the SBCb004 proteins). Patatin-like proteins exhibit 
lipid acyl hydrolase activity, a function apparently not required in the tubulysin pathway. 
Therefore, to obtain further insights into the potential functions of these genes in the tubulysin 
pathway, we aimed to inactivate these genes in the both the An d48 and the SBCb004 wild type 
strain. 
 
 
3.4.1  Knockout mutagenesis of tubA  
   I was able to generate the insertion knockout mutants of genes tubA in both natural producer 
strains. The construction of gene inactivation was accomplished by homologous recombination in 
the encoding regions. Oligos were designed to amplify the knockout region in the middle of target 
gene and also to introduce a stop codon inside. In strain SBCb004, primer pair ctubA-a and 
ctubA-b were used to knockout gene tubA (Figure 3.15, Table 2.7). The inactivation mutant of 
tubA was also obtained in strain An d48.  
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Figure 3.15  Inactivation of tubA and orf1 in SBCb004. 
(A) Genetic organization of chromosomal DNA in SBCb004 wild type.   
(B) Genetic organization of chromosomal DNA in mutant SBCb004-tubA–. From left to right: tubA 
truncated at the 3′ end (tubA′), pCR2.1-TOPO vector backbone, tubA truncated at the 5′ end (tubA″).  
(C) Genetic organization of chromosomal DNA in mutant SBCb004-orf1–. From right to left: orf1 
truncated at the 3′ end (orf1′), pCR2.1-TOPO vector backbone, orf1 truncated at the 5′ end (orf1″).  
(D) PCR reactions for verification of SBCb004-tubA mutant: PCR D1 yield a product of 1.1 kb from the 
mutant with primers tubA-c and pTOPO-in; PCR D2 yield a product of 2.3 kb from the mutant with 
primers pTOPO-out and tubA-d; PCR D3 amplify a product (2.3 kb) only from the wild-type with primers 
tubA-c and tubA-d.  
(E) PCR reactions for verification of SBCb004-orf1 mutant: PCR E1 yield a product of 1.8 kb from the 
mutant with primers orf1-d and pTOPO-out; PCR D2 yield a product of 2.1 kb from the mutant with 
primers pTOPO-in and orf1-c; PCR D3 amplify a product (2.8 kb) only from the wild-type with primers 
orf1-c and orf1-d.  
In the figure, the designation ‘wt’ represents the wild type of SBCb004, ‘1’ represents SBCb004-tubA– 
exconjugant, and ‘2’ and ‘3’ represents two distinct clones of SBCb004-orf1– exconjugant. All primers 
listed are shown in Table 2.7. 
 
 
   By HPLC-MS analysis, mutant SBCb004-tubA– was found to produce similar amount of 
pretubulsyin A with the wild type SBCb004 strain, and in no case tubulysin A presents in the 
culture extracts. Only small amount of additional pretubulysin derivatives were also detected, 
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including the tyrosine pretubulysin A (33), N-desmethyl 12-keto pretubulysin A (25), N-
desmethyl 12-hydroxy pretubulysin A (26), as well as the N-hydroxymethyl 12-keto pretubulysin 
A (32) (Table 3.3). Except the only hydroxyl pretubulysin N-hydroxymethyl 12-keto pretubulysin 
A (32) produced in tiny amount, no other mature tubulysins that incorporate acyl group were 
observed from the mutant SBCb004-tubA–. Similar result was obtained from the tubA knockout 
mutant in strain An d48 (Figure 3.16). It proved that no function of acyl transferase was applied 
in the tubA inactivation mutants. This fact suggests that TubA may serve as one (or both) of the 
missing acyltransferases in tubulysin assembly. Till now, no more proof was draw for the 
acylation function from the discovery of natural strain. To further confirm this hypothesis, in vitro 
assay of expressed TubA protein is necessary to carry out in the future. 
 
 
Figure 3.16  HPLC-MS analysis (BPC) of the An d48 wild type and mutant An d48-tubA–.  
Peaks corresponding to tubulysin D (1), E (2), F (3) and pretubulysin D (5) are indicated.  
(A) An d48 wild type.  
(B) Mutant An d48-tubA–.   
 
 
3.4.2  Knockout mutagenesis of orf1  
   Given the operon structure of genes orf1-tubZ-orf2, I anticipated polar effects on tubZ and orf2 
from disruption of orf1, and thus inactivation of orf1 was assumed to knockout the entire operon. 
I have shown previously that insertion mutants of tubZ in both the An d48 and SBCb004 produce 
more pretubulysin D or A and substantially less tubulysin D or A than the respective wild type 
strains [109; 127]. The production profile from the orf1 mutant in both strains (SBCb004-orf1– 
and An d48-orf1–) closely resembled that of the tubZ knockout strain (Figure 3.17). This result 
confirms that those strains must contain an additional cyclodeaminase function, capable of 
supplying L-pipecolate to the assembly line in the absence of a functional TubZ. The orf1 and 
tubZ inactivation mutants in both strains were also found to produce small amounts of tubulysin 
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Figure 3.17 High-resolution MS 
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(A) SBCb004 wild type.  
(B) Mutant SBCb004-tubZ–. 
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   Tandem high-resolution mass spectrometry, as described previously, was applied to estimate 
the structures of this new group of compounds. On the basis of relative formula estimation and 
the comparative analysis of MSn fragmentation pattern between the unknown compounds (mass + 
74) and corresponding known tubulysins, this new group of compounds were assumed to share a 
similar structure: tubulysin binding with a molecular of glycerol at the C-terminal. Detailed MS2 
fragmentation pattern analysis of compound 35 from An d48-orf18– mutant is shown in Figure 
3.20. The proposed structures of the metabolites and all the fragments, the molecular formulae 
and calculated molecular masses of the fragments, and the experimentally-determined molecular 
masses all fit well to the estimated structure: tubulysin D‒glycerol ester (Figure 3.22).  
 
   In order to confirm the prediction, two kinds of 13C labeled glycerols were used as feeding 
substracts to carry out the feeding experiment in mutant An d48-orf18. As expected, the result 
perfectly showed the incorporation of glycerols in compound 35 with either 13C labeled glycerol 
substrracts (Figure 3.21). All these results proved that the structure of compound 35 should be the 
tubulysin D‒glycerol. However, neither the tandem high-resolution mass spectrometry mass 
analysis nor the feeding experiments with 13C labeled glycerols can elucidate the detailed binding 
carbon of glycerol to tubulysin. Therefore, based on these foundings, my colleague Dominik 
Pistorius isolated and purified compound 35, and the structure was finally identified via NMR 
that the C1 of glycerol molecular binds to the C-terminal of tubulysin (Figure 3.22).  
 
   By analyzing the orf18 knockout mutants in two strains, a series of tubulysin-glycerol 
metabolites were identified, including the tubulysin D‒glycerol (34), tubulysin E‒glycerol (35), 
pretubulysin D‒glycerol (36) and N-Desmethyl 12-keto pretubulysin D‒glycerol (37) from strain 
An d48-orf18–, as well as tubulysin A‒glycerol (38), tubulysin B‒glycerol (39), pretubulysin 
A‒glycerol (40) and N-Desmethyl 12-keto pretubulysin A‒glycerol (41) from strain SBCb004-
orf18– (Table 3.4, Figure 3.22). The production profiles of orf18 mutants in both strains are the 
same: the major tubulysin products change from tubulysin D and E or A and B to their 
corresponding glycerol ester compounds (Table 3.5). In addition, these glycerol ester compounds 
also appeared in the wild type strain when I re-analyzed the production of SBCb004 (Table 3.5).  
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Figure 3.21  Feeding study with 13C labeled glycerol in mutant An d48-orf18–.   
Shown is the peak of the new found compound (35). 
(A) Absence of supplementation.   
(B) Supplementation with 2-13C-labeled-glycerol. 
(C) Supplementation with globle-13C-labeled-glycerol.   
 
 
Table 3.4  More novel metabolites identified in An d48 and SBCb004 mutants (Continue to Table 3.3). 
Metabolites in strain An d48 Metabolites in strain SBCb004 
No
. 
Compound name Mass 
[M+H]+ 
No
. 
Compound name Mass   
[M+H]+ 
34 Tubulysin D-glycerol 902.5 38 Tubulysin A-glycerol 918.5 
35 Tubulysin E-glycerol 888.5 39 Tubulysin B-glycerol 904.5 
36 Pretubulysin D-glycerol 744.4 40 Pretubulysin A-glycerol 686.39 
37 N-desmethyl 12-keto pretubulysin D-
glycerol 
744.4 41 N-desmethyl 12-keto pretubulysin A- 
glycerol 
686.39 
 
 
  
Figure 3.22  Proposed structures of tubulysin
 
 
Table 3.5   Major production profile of SBCb004 wild type and the patatin gene 
 
N-desmethyl 12-keto pretubulysin A 
N-desmethyl 12-keto pretubulysin A-glycerol
Pretubulysin A 
Pretubulysin A-glycerol 
Tubulysin A 
Tubulysin A-glycerol 
Tubulysin B 
Tubulysin B-glycerol 
*The peak area integration from the HPLC
the percentage was calculated relative to an internal standard
 
 
   Based on the high homology of 
were first supposed to carry out the same catalytic function
‒glycerol esters. 
SBCB004 WT SBCb004-orf17– mutant 
5.4% 0.5% 
 3.4% 0.5% 
8.6% 2.0% 
4.8% 4.6% 
20.3% 1.0% 
0.7% 0.3% 
20.0% 0.6% 
0.5% 0.4% 
-MS spectrometry represents the yield of each compound, and 
 Stigmatallin. 
the two patatin genes orf17 and orf18 (similarity
 in the tubulysin biosynthesis
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knockout mutants*.  
SBCb004-orf18– mutant 
1.2% 
12.6% 
6.3% 
16.5% 
4.0% 
50.5% 
3.0% 
43.7% 
 80%), they 
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However, SBCb004-orf17– mutant showed a different production profile comparing to that of the 
orf18 inactivation mutant. Although the tubulyisn−glycerol esters were observed from orf17 
mutant, not like its partner orf18 their yields were lower than that of the wild type strain. 
However, they were still produced in comparative amounts to the other none glycerol tubulysins 
since the yields of all tubulysin derivatives produced in SBCb004-orf17– were very low (Table 
3.4). One possible explanation for this might be that the inactivation of orf17 affects the NRPS-
PKS proteins’ transcription in the tubulysin biosynthesis. In the tubulysin biosynthetic gene 
cluster, gene orf17 overlapped with tubF for 83 bp. Therefore when gene orf17 is knocked out by 
insertion mutagenesis, the truncated orf17’ and the genes on the pTOPO vector backbone may 
affect, and further interrupt the transcription of TubF, resulting in a dramatic decrease of 
tubulysin production.  Of course, more evidence will be needed to prove my assumption. 
 
   The above results drew me to consider the roles of patatin genes in the tubulysin biosynthesis. I 
supposed the tubulysin-glycerol ester to be the originally biosynthesized tubulysin products in the 
wild type strains. The glycerol might be attached to the C-terminal of tubulysin structure by the 
TE domain when the intermediate pretubulysin is released from the assembly multienzymes. As 
patatin-like proteins, both Orf17 and Orf18 are assigned the function of acyl hydrolase activity. 
Thus they are capable to cut the bound glycerol from the tubulysin ester molecular, resulting in 
the common known tubulysin structures. When patatin gene is inactivated, the hydrolysis step is 
jumped over so that the tubulysin‒glycerol would be kept as major products instead. In the 
SBCb004 wild type, the pretubulysin‒glycerol family compounds (40 and 41) are produced in 
similar level to their corresponding pretubulysins, but the tubulysin‒glycerol family compounds 
(38 and 39) are yielded much less. This fact indicates that the patatin protein(s) prefer to use the 
matural tubulysins as their substracts and reveal better catalytic ability to them than the 
pretubulysin family compounds. 
 
 
3.4.4  Promoter insertion into strain SBCb004 
   Developing natural products as drug leads critically depends on obtaining sufficient amounts of 
the target compounds. The tubulysins are produced at relatively low yields by the natural 
producer strains An d48 (0.48 mg/ml tubulysin D) and SBCb004 (0.35 mg/ml tubulysin A). 
Furthermore, the titers of the tubulysin variants are even lower. These observations prompted us 
to look for molecular methods for increasing the tubulysin yields. It has been previously 
demonstrated that overexpression of single genes or multigene transcriptional units by promoter 
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exchange in other myxobacterial strains can lead to increased secondary metabolite formation 
[98; 137-139]. Thus, I aimed to insert a strong constitutive Tn5-derived npt promoter [139] 
directly in front of the tubulysin core gene cluster tubB–tubF in strain SBCb004. This strategy 
had been used successfully for myxochromide and ajudazol overproduction in M. xanthus and 
Chondromyces crocatus, respectively [139] 
 
   Tn5 promoter insertion was also achieved by homologous recombination (experiment was 
carried out similarly as the other gene knockout) (Figure 3.23). And the generated clones bearing 
the inserted promoter (SBCb004-Tn5) were confirmed by PCRs and sequencing (data not shown). 
Cultures of SBCb004-Tn5 were grown in triplicate alongside the SBCb004 wild type strain. 
Yields of the tubulysins as judged by integration of peak areas in the base peak chromatagram 
were calibrated against a second set of metabolites produced by the SBCb004 strain, the 
stigmatellins A, B and C [140]. The amounts of three major products tubulysin A, pretubulysin A, 
and N-desmethyl 12-keto pretubublysin A were calculated as a percentage of the yields of the 
internal standard (Figure 3.23). Unfortunately, the inserted Tn5 promoter did not upregulate the 
production, but instead decreased the titers of all the major metabolites by one-third relative to the 
wild type strain. A possible explanation for this finding is that the promoter insertion method 
somehow affected normal expression of the tubulysin assembly line, but determining the exact 
cause of the reduction in yields will require further investigation.  
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Figure 3.23  Tn5 promoter inserted mutant in SBCb004 strain: SBCb004-Tn5. 
(A) Genetic organization of chromosomal DNA in SBCb004 wild type.   
(B) Genetic organization of chromosomal DNA in mutant SBCb004-Tn5. From left to right: tubZ, orf1, 
tubB’s first region (1 kbp), pCR2.1-TOPO vector backbone, Tn5 promoter, complete gene tubB.   
(C) Comparison of three major tubulysin products (tubulysin A [1], pretubulysin A [14], and N-desmethyl 
12-keto pretubulysin A [18]) between SBCb004-Tn5 mutant and SBCb004 wild type.  The second product 
of SBCb004 strain stigmatellins were used as the internal standard, and the compounds yields (%) in two 
strains were calculated by the percentage to the stigmatellins’ production. 
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3.5   Heterologous expression and genetic engineering of the tubulysin 
biosynthetic gene cluster using Red/ET recombineering 
 
 
   In order to deepen the understanding of the post-assembly line aspects of tubulysin biosynthesis, 
and to facilitate the engineering of further derivatives for evaluation as drug leads, I endeavored 
to reconstitute the entire gene cluster using Red/ET recombineering technology.  
 
 
3.5.1  Reconstitution of the tubulysin biosynthetic gene cluster of Cystobactor sp. SBCb004 
   The tubulysin biosynthetic gene cluster from strain SBCb004 was found to be located on two 
cosmids (Cos DL18 and AP17) within a cosmid genomic library (data not shown). Cos DL18 
contained the 5′ end of the gene cluster (ending in the middle of tubD), while the 3′ end was 
located on Cos AP17 (starting in the middle of tubC) (Figure 3.22A and B); the region of overlap 
which encompassed the tubC and tubD genes, was ca. 14 kbp. As a first step in reconstituting the 
cluster, I replaced the pSuperCos cosmid backbone and the imcompleted tubD gene on Cos DL18 
with a cassette containing the p15A replication origin (p15A ori), an inverted repeat (IR), and a 
kanamycin selection marker flanked by a NheI site, resulting in plasmid pUp (Figure 3.22C). 
p15A is a low copy origin, which has been found to aid efficient further Red/ET modification 
steps, the NheI site facilitated subsequent cluster assembly, while the inserted IR was part of the 
designed transposition system which enables efficient integration of the cluster into the host 
genome. Cos AP17 was also modified by replacement of the pSuperCos backbone as well as the 
tubC fragment with a gene cassette containing the pUC origin of replication and an ampicillin 
resistance gene flanked by a NheI site (Figure 3.22C). To enable efficient selection in the 
subsequent ‘stiching’ step, a zeocin resistance gene with a flanking NheI site was introduced at 
the opposite end of the cosmid to yield plasmid pDown (Figure 3.22C). Both pUp and pDown 
were then digested with NheI (Figure 3.22D). The resulting 29 kbp fragment from pDown was 
ligated with the linearized pUp, and the ligation mixture was transformed into E. coli GB05-red 
cells. Screening for zeocin resistance yielded the desired construct p15A-Tub which harbors the 
complete 11 tubulysin biosynthetic genes in the correct orientation (Figure 3.22E). The 
reconstituted tubulysin gene cluster on plasmid p15A-Tub is nearly identical to the parent in 
SBCb004. The one difference is that the wild type genes tubC and tubD overlap by 11 bp, while 
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on plasmid p15A-Tub, they are separated by 29 bp (which includes the introduced NheI site) 
(Figure 1E).  
 
   A transposition cassette comprised of two IRs, the corresponding MycoMar transposase (Tps), 
the origin of transfer oriT, and an Amp resistance gene, was designed to enable transfer and 
integration of the gene cluster into the chromosome of heterologous host strains. The mariner 
transposon MycoMar is frequently used in Gram-negative hosts for genetic modification. In the 
heterologous expression of epothilone and myxochromide S [98], the MycoMar transposon-
mediated transformation of large gene was more efficient than that of homologous recombination 
using a smaller construct. Thus, as a powerful delivery tool for large transgenes, it was employed 
in the tubulysin heterologous expression system to facilitate the transformation and integration of 
the gene cluster into the genome of host strains. The incorporation of oriT was previously shown 
to be necessary for transposon-mediated integration of plasmids into the chromosome of the P. 
putida strain [98]. Introduction of this cassette IR-Tps-Amp-oriT (the other IR is already on the 
plasmid) into construct p15A-Tub was also accomplished enabling the deletion of zeocin and 
several open reading frames downstream of the cluster (orf21-orf22-orf23), resulting in plasmid 
pTps-Tub. 
 
   The natural start codon of tubC is the rare TTG. As I worried that this would limit the efficiency 
of expression in the target heterologous hosts [141], I also aimed to alter the codon using Red/ET 
recombineering. First, I tried to insert a gentamycin resistance gene in front of tubC as well as to 
change the start codon to ATG, but no correct clones were obtained: all of the resulting 
recombinants incorporated a mutation at the 5' end of tubC. This problem had been encountered 
previously during attempts to insert a constitutive promoter in front of the myxochromide gene 
cluster (Y. Zhang, unpublished result). It may be the case that the expression of the downstream 
tubulysin gene cluster (tubC−tubF) when driven by the gentamycin constitutive promoter, is toxic 
to the E. coli host. Therefore, to stable the tubulysin heterologous expression plasmid in E.coli 
strain, I aimed to insert an inducible promoter 5' of tubC to regulate the expression of following 
genes. For this, I generated a gene cassette containing a Genta resistance gene and an inducible 
promoter tetR-Ptet. The tetR-Ptet is a tetracycline (Tet) based regulatory system which is generally 
used to selectively control downstream gene expression. It includes a tetracycline resistance gene 
tetR (encoding the tetracycline repressor protein TetR) and an 81 bp gene sequence which harbors 
bidirectional promoters which overlap with two highly homologous control sequences. In the 
absence of the inducer tetracycline, TetR protein dimers inhibit the bidirectional promoters by 
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binding to the two control sequences, shutting down the transcription of following gene/operon 
under Ptet which is opposite to tetR. When tetracycline is present, however, the TetR protein 
complexes with it in preference to the control region, resulting in expression of the target genes. 
The cassette was amplified by PCR using primers with short homology arms to enable integration 
between the tubB and tubC genes, as well as to modify the start codon; one version contained the 
original TTG start codon of tubC, and the second, a mutant ATG. The resulting fragments were 
then inserted into pTps-Tub. This strategy yielded the desired plasmids pTub-TTG and pTub-
ATG (Figure 1F) (The construct pTuy-TTG was generated by Shiping Shan). In these plasmids, 
the gentamycin resistance gene and the tetracycline inducible promoter tetR-Ptet are located in 
front of tubC, being a difference to the wild type cluster. The integrity of all obtained 
recombination constructs was verified by restriction analysis using a diagnostic set of enzymes, or 
by sequencing. 
 
 
 
  
Figure 3.24 Description of the 
(A) The indentified tubulysin biosynthetic gene cluster from strain SBCb004.
(B) Two overlapping cosmids Cos DL18 (harboring 5
end tub gene cluster).  
cloning strategy of tubulysin biosynthetic gene cluster 
 
′- end tub gene cluster) and Cos AP17 (harboring 3
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reconstitution.  
′- 
 86 
 
(C) A p15A-IR-Km cassette was used to modify Cos DL18 via Red/ET recombineering to replace the 
pSuperCos backbone as well as the tubD portion, resulting in plasmid pUp. Two rounds of Red/ET 
recombinations were carried out on Cos AP17, leading to the plasmid pDown. Cassette pUC-Amp was used 
to exchange the pSuperCos backbone and the tubC portion, while the inserted zeocin restriction gene was 
used as the selection marker in the following stitching step.  
(D) Digest both plasmids with NheI. Plasmid pUp was linearized, while plasmid pDown was cut into two 
pieces: a 29 kb fragment (with 3′ end tub gene cluster) and a 4 kb fragment.  
(E) Ligate the linearize pUp and 29 kb digested DNA fragment from pDown together to stitch the entire tub 
gene cluster together into one plasmid p15A-Tub.  
(F) Insert IR-Tps-Amp-oriT cassette onto the construct to generate a transpositional system. Then, two 
parallel modification cassettes Genta-TetR-Ptet-TTG and Genta-TetR-Ptet-ATG were inserted in front of 
gene tubC, resulting in two heterologous expression construct pTub-TTG and pTub-ATG, respectively. The 
constituted plasmids were confirmed by PvuII restriction analysis and sequencing. In the DNA gel figure, 
line “1–4” represented 4 distinct clones of plasmid pTub-ATG, whild “M” represented the DNA marker. 
 
 
3.5.2 Heterologous expression of the tubulysin gene cluster in Pseudomonads putida  
   Both constructs pTub-TTG and pTub-ATG were introduced into the host organism P. putida by 
triparental conjugation, with selection for kanamycin resistance on PMM medium (The 
experiments with strain P. putidas were carried out by Shiping Shan, including the transformation, 
fermentation, and product extraction.) For each construct, 5–10 randomly chosen clones were 
cultivated and the integration of the constructs into the genome was verified by colony PCR. 
Positive clones were then cultivated in PMM medium in the presence of tetracycline to activate 
the TetR-Ptet promoter, and the culture extracts were analyzed by HPLC-MS.  
 
   Two members of the pretubulysin subfamily, pretubulysin A and tyrosine pretubulysin A, were 
observed in the extracts of both P. putida::pTub-TTG and P. putida::pTub-ATG strains, although 
they were both produced at disappointingly low levels (the yield of pretubulysin A (14) from P. 
putida::pTub-TTG was approximately 0.04 µg/L, and that from P. putida::pTub-ATG was 0.2 
µg/L.)  (Figure 3.25). This result demonstrates that, as predicted, the core gene cluster contains all 
genes required to produce the polyketide-nonribosomal peptide skeleton of the tubulysins [102; 
127]. However, the fact that neither of the products incorporated the acyl groups of the mature 
tubulysins, demonstrated that at least some of the post-assembly line genes are absent from the 
heterologous expression construct (i.e. the acyl transferase might have been present, but unable to 
act due to the absence of a required oxidase). Alternatively, but much less likely some genes may 
not be expressed because the promoter(s) are not recognized in the heterologous host. 
Unexpectedly, I also detected trace amounts of tubulysin A in P. putida::pTub-TTG(ATG). A 
possible explanation for this finding is that another oxidase and/or acyltransferase encoded in the 
P. putida chromosome was able to complement the missing post-modification function(s) in 
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tubulysin A biosynthesis. I have previously observed a similar complementation event in strains 
An d48 and SBCb004: inactivation of the cyclodeaminase gene tubZ did not abolish biosynthesis 
of the tubulysins, and instead the mutant strains generated substantial amounts of pretubulysin 
D/A as well as small quantities of tubulysin D/A. This result suggested that the genomes harbored 
additional cyclodeaminase-encoding genes, and indeed BLAST analysis of the SBCb004 genome 
revealed two genes with homology to ornithine cyclodeaminasese [109; 127]. I assume that the P. 
putida genome encodes a number of oxidases and acyltransferases, and their efficiency with the 
tubulysins as substrates is low, explaining the small yield of tubulysin A from the heterologous 
expression strain. 
 
 
Figure 3.25  Main produced tubulysins by P.putida::pTub-ATG.  
0.1 mg/ml pipecolic acid was supplemented, and cultivation is at 30 oC. 
(A) HPLC-MS analysis (base peak chromatogram [BPC]) of P. putida::pTub-ATG. 
(B) The MS2 fragment pattern of tyrosine pretubulysin A (33). 
(C) The MS2 fragment pattern of pretubulysin A (11). 
 
 
   L-pipecolic acid serves as the starter unit for tubulysin biosynthesis. Reasoning that the Pip 
supply might limit the overall yields, attempt was carried out to increase tubulysin production by 
feeding Pip to cultures of P. putida::pTub-TTG(ATG). Although racemic D, L-pipecolic acid was 
used in all the experiments, only the L-isomer is incorporated into the tubulysins (Feeding 
experiment was carried out in M. xanthus::pTub-ATG. Data was shown in the following chapter, 
in Figure 3.27) [127]. As hoped, a substantial increase in tubulysin titers was obtained. For 
example, the production of pretubulysin A (14) by P. putida::pTub-ATG increased from 0.2 µg/L 
to 1.76 µg/L in the presence of 0.1 mg/ml supplemental Pip. Thus, it appears that the activity of 
the heterologous TubZ in P. putida limits the overall yields from the biosynthetic pathway.  
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   In order to explore the effect of the start codon on tubulysin biosynthesis in the heterologous 
expression strain, I compared the yields of pretubulysin A (14) from P. putida::pTub-TTG and P. 
putida::pTub-ATG. Production by strain P. putida::pTub-ATG containing the modified ATG start 
codon was higher than that incorporating the wild type TTG (0.2 µg/L vs. 0.04 µg/L). Similarly, 
in the presence of 0.1 mg/ml supplemental Pip, production of pretubulysin A (14) by the ATG-
modified strain was 1.76 µg/L, approximately three-fold higher than that by the TTG strain (0.66 
µg/L). This result supports the idea that the rare TTG codon can inhibit translation of TubC and 
ultimately lower the overall yields of the tubulysins. Thus, optimization of start codons may be a 
useful general strategy for improving titers from heterologous expression constructs in the future.  
 
   During heterologous expression of myxochromide S in P. putida, it was noted that the 
cultivation temperature dramatically affected the product yield: cultivation at 16 °C resulted in 
1000-fold more myxochromide S than incubation at 30 °C [71]. In order to test the effect of 
temperature on tubulysin heterologous expression in P. putida, P. putida::pTub-ATG was 
cultivated at both 30 and 16 °C. Surprisingly, an opposite result was obtained: under 
supplementation with 0.1 mg/ml Pip, the yield of pretubulysin A (14) at 30 °C (1.76 µg/L) was 2-
fold higher than that at 16 °C (0.84 µg/L). In the case of myxochromide S, a Pm promoter was 
introduced in front of the gene cluster in order to boost metabolite production by up-regulating 
expression of the biosynthetic genes. Thus, high expression at 30 °C may have resulted in 
improper folding and/or aggregation of the large PKS and NRPS proteins, so that the overall yield 
of myxochromides was reduced. In the case of tubulysin, however, expression is under the 
presumably weak, native promoter(s) from the SBCb004 genome. Thus, the influence of 
temperature on the P. putida::pTub-ATG strain is relatively small, and consistent with the general 
preference of P. putida for growth at 30 °C. 
 
 
3.5.3 Heterologous expression of the tubulysin gene cluster in Myxococcus xanthus 
   Given the closer relationship between Myxococcus xanthus and the native tubulysin producer 
SBCb004, I anticipated that M. xanthus might – despite its inferior growth characteristics – be a 
better heterologous expression host strain for tubulysin biosynthesis. To test this hypothesis, 
construct pTub-ATG was transformed into M. xanthus DK1622 by electroporation followed by 
selection for kanamycin resistance. Randomly selected clones were then cultivated and the 
integration of gene cluster was verified by colony PCR (Figure 3.26). Correct M. xanthus::pTub-
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ATG clones were then fermented in CTT liquid medium under tetracycline induction, and the 
culture extracts were analyzed by HPLC-MS. Expression of the gene cluster in DK1622 produced 
a similar metabolite profile as P. putida::pTub-ATG, but the tubulysins were obtained at higher 
yield (Figure 3.27). For example, in the presence of 0.1 mg/ml supplemental Pip, the yield of 
pretubulysin A (14) from M. xanthus::pTub-ATG (0.19 mg/L) was 100-fold higher than that from 
P. putida::pTub-ATG (1.76 µg/L). In addition, due to the higher titres, I was able to detect more 
tubulysin variants from the M. xanthus::pTub-ATG strain via their MS2 fragmentation pattern 
during HPLC-MS analysis. These variants included tyrosine pretubulysin A (33), N-desmethyl 
12-keto pretubulysin A (25), N-desmethyl 12-hydroxy pretubulysin A (26), N-desmethyl 
pretubulysin A (27), and also trace amounts of tubulysin A (6) (Figure 3.1 and Table 3.3). Again, 
biosynthesis of tubulysin A is likely due to adventitious action of oxidase and/or acyltransferase 
enzymes encoded in the M. xanthus DK1622 genome. 
 
   Supplementation with Pip also increased production of M. xanthus::pTub-ATG. In order to 
quantify the relationship between the Pip supply and pretubulysin production, I fed various 
amounts of Pip to M. xanthus::pTub-ATG. In order to estimate the production yield, a reference 
curve was generated using synthetic pretubulysin D (5) (kind gift of Prof. U. Kazmaier) [109]. 
Assuming that the ionization efficiency of the derivatives was the same as that for pretubulysin D, 
the yields of all tubulysins were judged based on their relative peak areas in the HPLC-MS 
chromatogram in comparison with the standard curve. Four individual clones of M. 
xanthus::pTub-ATG were grown in parallel, and the quantities of the two major products 
pretubulysin A (11) and tyrosine pretubulysin A (33) were determined from the average of the 
three values. Yields from the SBCb004 wild type strain were used as a benchmark (Figure 3.28). 
As the integration of the cluster into the M. xanthus genome was transposon-mediated, the site of 
integration is likely to vary between randomly-selected clones. In the case of Streptomyces, it has 
been observed that integration into different loci can affect the protein expression and production 
yield [142]. However, the four randomly selected clones, which likely represent different 
integration sites (though this was not directly determined), produced similar amounts of the 
tubulysins. For example, in the presence of 0.08 mg/ml supplementary Pip, the yields of 
pretubulysin A (11) from the four clones were 0.176, 0.154, 0.165, and 0.173 mg/L, respectively 
(average yield 0.167 ± 0.008 mg/L). A similar result was also observed when this marine 
transposon strategy was used to integrate epothilone and myxochromide gene clusters into M. 
xanthus  [98]. 
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Figure 3.26 Clony PCR of tubulysin heterologous expression construct in P. putida and M. xanthus.  
5′ end PCR amplified the tubA-orf2 region (2.4 kb) of the tub gene cluster with primer Cbt-A3 and Cbt-A4, 
and the 3′ end PCR amplified the orf17-orf18 region (2.5 kb) with primer Cbt-H3 and Cbt-G4 (Table 2.7).  
 
 
 
Figure 3.27  Feeding studies with pipecolic acid in strain M. xanthus::pTub-ATG. 
(A) HPLC-MS Analysis (Extracted Ion Chromatograph [EIC]) at m/z 686.5 [M+H]+ (pretubulysin A [14]). 
Fed pipecolic acid is a L-/D- mixture. 
(B) HPLC-MS Analysis (Extracted Ion Chromatograph [EIC]) at m/z 644.4 [M+H]+ (tyrosine pretubulysin 
A). Fed pipecolic acid is a L-/D- mixture. 
(C) HPLC-MS Analysis: supplementation with di-deuterium labeled L-pipecolic acid.  
(D) HPLC-MS Analysis: supplementation with di-deuterium labeled D-pipecolic acid. 
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In the case of SBCb004, production of both compounds initially increased during 
supplementation with Pip (to 0.14 mg/ml), but declined thereafter, suggesting an inhibitory effect 
on the cells. The yields of both metabolites from M. xanthus::pTub-ATG also initially increased 
with the concentration of Pip, but no further augmentation was seen at concentrations above 1 
mg/ml (Figure 3.28). In addition, in the case of pretubulysin A, the overall yields remained 
approximately 50% lower than that of supplemented SBCb004, although they were comparable to 
the non-supplemented wild type. These results confirm that the supply of L-pipecolate is limiting 
to tubulysin biosynthesis in both strains, but equally that supplementation can only boost 
metabolite quantities to a modest extent. It is worth mentioning that the yield of tubulysin is 
currently limiting further development of the compounds as neither synthetic nor fermentative 
approaches have led to sufficient production strategies. Only the less potent pretubulysin offers 
access in reasonable yields via chemical synthesis [109]. 
 
 
Figure 3.28  Feeding pipecolic acid into strain SBCb004 (dashed line) and M. xanthus::pTub-ATG 
(solid line).   
(A) Yield of pretubulysin A. 
(B) Yield of tyrosine pretubulysin  A. 
 
 
3.5.4  Genetic modification of the tubulysin heterologous expression system  
   As noted earlier, the conserved tubulysin biosynthetic gene cluster in both An d48 and 
SBCb004 strains contains several open reading frames whose functions have been unclear to date. 
These include the genes tubA, orf2, and orf1 at the 5′ end of the gene set. The observation that 
they share a high degree of mutual sequence homology (56–78% identity/73–90% similarity) 
[127] suggests that they play a role in the biosynthesis. To obtain further insights into the 
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potential functions of these genes in the tubulysin pathway, I aimed to inactivate these genes on 
the pTub-ATG expression construct. 
 
   For this, I replaced the target genes by a chloramphenicol (Cm) resistance gene, using Red/ET 
recombineering. As genes orf1, tubZ, and orf2 are likely to form an operon, deletion of any gene 
would likely affect the function of all downstream gene(s) due to polar effects. Therefore, in 
order to obtain the clearest picture from the results, in each case, I deleted the target gene together 
with any downstream gene(s) (Figure 3.30). The deletion constructs pTubA, pOrf2, pTubZ 
(deletion of both tubZ and orf2), and pOrf1 (deletion of the entire orf1-tubZ-orf2 operon) were 
screened using low salt LB plates containing Amp and Cm, and then verified by restriction 
analysis (Figure 3.29). The modified constructs were transformed into M. xanthus DK1622, and 
the production profile of positive clones was analyzed by HPLC–MS. 
 
 
Figure 3.29   Restriction analysis of the gene deletion constructs with enzyme PvuII.  
The size of restricted bands that changed in the deletion constructs are shown as following. The changes of 
band are based on the restriction of construct pTub-ATG. And only the bands bigger than 1 kb are listed. 
pOrf1: Arised band: 5124 bp, 2579 bp; Disappeared band: 5285 bp, 4447 bp. 
pTubA: Arised band: 3554 bp, 1391 bp; Disappeared band: 5285 bp. 
pOrf2: Arised band: 5124 bp; Disappeared band: 5285 bp. 
pTubZ: Arised band: 5124 bp, 3758 bp; Disappeared band: 5285 bp, 4447 bp.  
 
 
   The resulting strains still produced both pretubulysin A (11) and tyrosine pretubulysin A (33), 
albeit in reduced yields. For example, when fed with saturating Pip (0.08 mg/ml), the titers of 
pretubulysin A from all mutants was lower than that from M. xanthus::pTub-ATG strain (pTubA 
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24% relative yield, pOrf2 45%, pTubZ 51%, and pOrf1 18%) (Figure 3.30). In addition, even 
with Pip supplementation (0.08 mg/ml), no tubulysin A was detected from these strains. The 
production of the pretubulysin subfamily compounds in the absence of orfs 1, 2 and tubA 
indicates that these genes are not essential for assembling the tubulysin core structure. However, 
the reduction in yield relative to that from the pTub-ATG strain shows that they nonetheless 
contribute to pretubulysin biosynthesis in some manner. 
 
 
Figure 3.30  Genetic modification of tubulysin heterologous expression system.  
Left: Tubulysin 5′ end gene deletion in the deletion constructs. Right: The HPLC-MS analysis (Extracted 
Ion Chromatograph [EIC]) at m/z 686.5 [M+H]+ (pretubulysin A) and m/z 644.4 [M+H]+ (tyrosine 
pretubulysin A) of the corresponding deletion constructs in M. xanthus strain. 0.08 mg/ml pipecolic acid 
was supplemented.  
(A) M. xanthus::pTub-ATG strain. 
(B) M. xanthus::pTubA deletion strain 
(C) M. xanthus::pOrf2 deletion strain. 
(D) M. xanthus::pTubZ deletion strain. 
(E) M. xanthus::pOrf1 deletion strain. 
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3.6  Discovery of the missing monooxygenase in the tubulysin 
biosynthetic gene cluster 
 
 
   All evidence suggests that the tubulysin oxidase(s) and possibly a second acyl transferase are 
absent from both clusters in strains An d48 and SBCb004, and so are presumed to be located 
elsewhere in the genomes. Such split cluster PKS/NRPS architecture is unusual for Streptomyces, 
but has increasing precedent in the myxobacteria [119-121]. Therefore, the BLAST analysis of 
the SBCb004 genome data was used to identify multiple candidate monooxygenases, whose 
involvement in tubulysin assembly was evaluated using a combination of knockout mutagenesis 
and heterologous expression. 
 
 
3.6.1 Identification of candidate genes for the missing monooxygenase in the SBCb004 
genome  
   In order to locate the missing oxygenase(s), a P450-encoding gene ajuJ from the ajudazol 
biosynthetic gene cluster of the myxobacterium Chondromyces crocatus Cm c5 [143] was used as 
a probe in a BLAST analysis [115] of whole genome sequencing data from strain SBCb004, 
obtained by shot-gun sequencing using 454 technology [113; 114]. This analysis identified an 
unprecedented number of 49 candidate oxygenases. Annotation of the flanking regions in each 
case identified six P450 genes and one monooxygenase gene that were co-located with at least 
one acyl transferase, indicating their possible involvement in the tubulysin pathway (Figure 3.31).  
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Figure 3.31 Annotation of the flanking regions of these identified monooxygenase genes from seven 
contigs of the SBCb004 genome. 
(A) Gene annotation from contig 24 in SBCb004 Genome.  
(B) Gene annotation from contig 45 in SBCb004 Genome. 
(C) Gene annotation from contig 302 in SBCb004 Genome.  
(D) Gene annotation from contig 333 in SBCb004 Genome. 
(E) Gene annotation from contig 399 in SBCb004 Genome. 
(F) Gene annotation from contig 1042 in SBCb004 Genome. 
(G) Gene annotation from contig 633 in SBCb004 Genome. 
 
 
3.6.2 Knockout mutagenesis of the monooxygenase candidates in the SBCb004 genome  
   In order to study their involvements in the tubulysin pathway, these seven genes were targeted 
by knockout mutagenesis in SBCb004, using the method described earlier. The tubulysin 
production profiles of six mutants (SBCb004-24P–, SBCb004-45M–, SBCb004-302P–, SBCb004-
333P–, SBCb004-399P–, and SBCb004-1042P–) were essentially identical with that of the 
SBCb004 wild type, indicating that the mutated enzymes are not involved in tubulysin assembly. 
However, culture extracts of a strain containing a mutated P450 gene from contig 633 (633P1) 
produced only several pretubulysin subfamily compounds pretubulysin A (11), N-desmethyl 12-
keto pretubulysin A (25), N-desmethyl 12-hydroxy pretubulysin A (26), and N-desmethyl 
pretubulysin A (27) (Figure 3.1 and Table 3.3), while tubulysin variants incorporating post-PKS 
hydroxylation were completely absent (Figure 3.32). In addition, the production of the 
pretubulysins decreased dramatically. This result identified gene 633P1 as a promising candidate 
for one of the missing oxygenases. However, it is unclear why the yields of the pretubulysin 
should have been affected by its inactivation. 
 
 
  
Figure 3.32  HPLC-MS analysis (BPC) of the SBCb004 
Peaks corresponding to tubulysin A (
(36) are indicated.  
(A) SBCb004 wild type.  
(B) Mutant SBCb004-633P1–.  
 
 
Figure 3.33  High-resolution MS analysis
EIC at m/z 686.5 [M+H]+  (pretubulysin A [
(A) SBCb004 wild type.  
(B) Mutant SBCb004-633P1–. 
(C) Mutant SBCb004-633P2–.  
 
 
 
wild type and mutant SBCb004
6), tubulysin B (7), pretubulysin A (11) and pretubulysin A
 
 
 of 633P1 and 633P2 knockout mutant. 
11]) and m/z 844.4 [M+H]+ (tubulysin A [
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-633P1–.  
-glycerol 
6]). 
  
Interestingly, gene 633P1
an acyltransferase, 633AT (Figure 3.
participation in tubulysin biosynthesis. However, inactivation of gene 
yielded a metabolite profile identical to that of the 
involvement in the pathway 
post-assembly line oxidations in tubulysin assembly. 
 
 
3.6.3 Co-expression of the t
   To attempt to confirm the involvement of gene 
introduced into construct pTub
promoter, via Red/ET recombination 
resulting pTub-633P1 construct was conjugated into 
tetracycline (Experiment was 
that strain P. putida::pTub-633P1 generated pretubulysin A
but that no metabolites incorporating 
present. These data were surprising given the clear results of inactivation of 
type strain, but may indicate that the P450 requires additional gene products to be present in order 
to be active, which are currently absent from the heterologous expression construct (e.g. 
ferredoxins and ferredoxin reductases). In any case, fu
function of 633P1 as the tubulysin monooxygenase. 
 
Figure 3.34  The generated heterol
 is located in close proximity to a second P450 gene 
31G), identifying these additional genes as candidates for 
633P2
wild type strain, likely excluding its 
(Figure 3.33). Thus, the P450 gene 633P1 may carry out both of the 
 
ubulysin gene cluster and gene 633P1 in P. putida
633P1 in tubulysin biosynthesis, the gene was 
-ATG as a cassette along with a zeocin resistance gene and a P
(Experiment was did by Shiping Shan) 
P. putida, and expression ind
done by Shiping Shan). However, analysis by HPLC
 (11) and tyrosine pretubulysin A
post-assembly line hydroxylation and/or acylation were 
rther work will be required to confirm the 
 
 
ogous expression construct pTub-633P1. 
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4   SUMMARY AND CONCLUSION 
 
 
   The present thesis deals with the identification and characterization of tubulysin biosynthetic 
pathways. I specially focused on the functional analysis of protein TubZ, knockout mutagenesis 
of tubA, as well as orfs 1, 17 and 18, discovery of novel tubulysin derivatives, heterologous 
expression of the tubulysin gene cluster in other host strains, and identification of the post-
assembly line monooxygenase.  
 
 
4.1   Identification of tubulysin biosynthetic gene cluster 
  
  Recently, Cystobacter sp. SBCb004 was found out to be a third tubulysin producer strain. In 
common with Archangium gephyra Ar315, SBCb004 generates tubulysins A, B, C, G and I, 
which incorporate tubutyrosine instead of the tubuphenylalanine of tubulysins D, E, F and H. 
Based on a cosmid library coupled with complete genome sequence of strain SBCb004, I could 
identify the tubulysin biosynthetic gene cluster in the SBCb004 strain. Comparison analysis of the 
cluster in both SBCb004 and An d48 strains reveals the anticipated hybrid NRPS-PKS core genes 
and six additional small genes. The gene sets show a conserved architecture, allowing the 
straightforward determination of the cluster boundaries in two myxobacteria strains. 
Unfortunately, like its An d48 counterpart, the SBCb004 tubulysin gene cluster does not contain 
any gene encoding post-modification tailoring function. 
 
 
4.2   Starter unit supplement of the tubulysin assembly 
 
   A gene encoding a lysine cyclodeaminase (tubZ), identified at 5′ end of the tubulysin gene 
cluster, was assumed to participate in provision of the starter unit pipecolic acid in the tubulysin 
pathway. To directly probe the function of tubZ, I inactivated the gene by insertional mutagenesis 
in both An d48 and SBCb004 strains. The resulting mutants An d48-tubZ– and SBCb004-tubZ– 
were first expected to be deficient in tubulysin biosynthesis, but actually they produced tubulysin 
D or A at approximately 3%-5% of wild type levels instead. The continued availability of 
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pipecolic acid to the pathway was attributed to the presence of additional lysine cyclodeaminase 
function(s) in both strains.    
 
   The TubZ protein was also expressed in E.coli and analyzed in vitro. As expected, the assay 
shows that TubZ is able to form the starter unit pipecolic acid. In addition, it is also proved that 
TubZ catalyze the reaction only from L-lysine to L-pipecolic acid. Feeding studies in strain An 
d48 further confirmed this result that TubZ specially took the L-lysine as its catalysis substrate 
since only L-lysine was incorporated into the final tubulysin products.  
 
 
4.3   Discovery of novel tubulysin derivatives  
 
   Prior to this study, only nine tubulysins have been described from the myxobacterial strains [40]. 
Here I found out the presumed first enzyme-free intermediate, pretubulysin D (in strain An d48) 
and pretubulysin A (in strain SBCb004), in the tubulysin pathway from tubZ knockout mutants. 
The metabolites were subsequently detected in the corresponding wild type strains, supporting 
their intermediacy in the biosynthesis. The “pretubulysin” is only known as a theoretical structure 
before my works. Now, for the first time, the intermediates were found out to be produced 
naturally.  
 
  The founding of pretubulysins encouraged me to detailedly investigate the productions of 
tubulysin natural producer strains An d48 and SBCB004 again. Finally, through the combination 
of high-resolution tandam mass spectrometry and feeding experiments, I was able to found out 
the natural biosynthesises of additional 22 tubulysin derivatives. Their assemblies all rely on the 
same core NRPS-PKS modules. In the patation knockout mutants, I could also identify another 8 
novel derivatives, the tubulysin‒glycerol ester compounds (This will be addressed in the chapter 
4.4.3).  
 
   The identification of novel tubulysins in A. disciformis and Cystobacter reveals new aspects of 
the biosynthesis, as well as supporting earlier proposals. For example, my results strongly suggest 
that pretubulysin D/A are the products of the hybrid PKS-NRPS in each strain. More generally, 
the data show that several steps in the pathway do not go to completion (Figure 4.1). The 
presence in the extracts of pretubulysins, and compounds 12, 13, 19, 20 and 23, 24, 30, 31 
missing one or more of the oxidation and acylation reactions, demonstrates that post-assembly 
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line modification is relatively inefficient, even in the wild type strains. This observation is 
consistent with the absence of obvious tailoring genes (oxidases and perhaps an acyltransferase) 
within the clusters, arguing for a lack of co-evolution of this portion of the pathways. The N-
methyltransferase domain of subunit TubC also operates only imperfectly – in fact, the N-
desmethyl compounds (14–18) and (25–29) constitute major metabolites of the strain. Apparently, 
the lack of N-methylation somehow induces skipping of some, if not all of the reductive steps 
carried out by the adjacent PKS module. However, these activities do occasionally function, as 
the corresponding hydroxyl (15, 26) and methylene (16, 27) analogues are produced at low levels. 
Processing by post-assembly line enzymes at C11 can also occur, and is more efficient when full 
reduction has taken place at the adjacent C12 position. This mechanism is inconsistent, however, 
with the discovery in extracts of N-hydroxymethyl 12-keto pretubulysins (21, 32), as the 
reductive steps have been bypassed even though the N-methyl group was added. One possible 
explanation is that, in a small number of cases, the N-methyl is hydroxylated while the 
intermediate is attached to the assembly line, and this modification also disrupts reductive 
processing by the PKS module. Finally, the truncated phenylalanine analogues (22, 33) appear to 
arise from failure of the final chain extension step with malonate, catalyzed by TubF. At this 
stage it is not clear whether premature release from the assembly line is spontaneous due to 
stalling of the intermediate at the TubE/TubF interface, or alternatively enzyme-catalyzed, for 
example by the TE domain, as demonstrated in pikromycin biosynthesis [144]. 
 
It is intriguing to consider whether the apparent ‘failure’ of various enzymes in the tubulysin 
pathway is in fact favored by evolution to increase the diversity of structures generated by the 
strain, a proposal known as the ‘screening hypothesis’ [145]. Indeed, the production of sometimes 
large families of metabolites which differ in their core structures appears to be a general feature 
of myxobacterial secondary metabolism, in which post-assembly line processing is relatively 
minimal [31]. However, relevant information on the biological roles of the various tubulysins for 
the producing organisms is lacking at present. Clearly, though, the PKS-NRPS can process a 
range of structurally-divergent intermediates, encouraging the view that the assembly line could 
be tailored by genetic engineering to produce further variants. Similar observations have been 
made for the epothilone assembly line, from which multiple epothilone derivatives have been 
generated by directed modification. In the meantime, the novel analogues can be targeted for total 
synthesis, in order to obtain sufficient materials to extend the ongoing structure-activity studies of 
the tubulysin metabolites.  
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Figure 4.1  Causes for the biosynthetic diversity in tubulysin assembly. 
 
 
4.4   Inactivation mutagenesis of tubulysin pathway 
  
  In order to investigate the roles of the accessory genes in the tubulysin biosynthesis, I carried out 
the insertional inactivation mutagenesis in both wild type strains An d 48 and SBCb004.  
 
4.4.1  TubA ‒ the possible acyl transferase in tubulysin biosynthesis 
   The inactivation of gene tubA in two natural producer strains An d48 and SBCb004 resulted in 
none-acyl tubulysin productions. Further proof was also draw from a tubA knockout in the 
heterologous expression system in strain M. xanthus DK1622. Such fact strongly suggests that 
TubA may serve as at least one of the post-modification acyltransferase in the tubulysin 
biosynthesis.  
 
4.4.2  orf1 and orf2 may be involved in tubulysin biosynthesis 
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   Inactivation of the gene orf1 or orf2 (orf2 only succeeded in the heterologous expression 
system.) resulted in the accumulation of the pretublysin, suggesting their effects on the extent of 
post-assembly line modification. The results could not prove their functions clearly, but the 
pretubulysin subfamily compounds production in the absence of orf1 and orf2 indicates that they 
still contribute to pretubulysin biosynthesis in some manner even though they are not essential for 
assembling the tubulysin core structure. 
 
4.4.3  Function of patatin genes orf17 and orf18  
   Inactivation of the patatin gene orf18 in both An d48 and SBCb004 strains opened a new 
window for the tubulysin biosynthesis. The novel tubulysin–glycerol or pretubulysin–glycerol 
compounds in the orf18 inactivation mutants clearly indicates the function of Orf18: it cuts off 
the bound glycerol from biosynthesized tubulysin–glycerol and results in the general matural 
tubulysins, although currently we have no idea how the glycerol is attached on. Gene orf17 shows 
high similarity to orf18 and is supposed to have the same function. However, inactivation of 
orf17 in strain SBCb004 showed a different production profile: instead of glycerol ester 
compounds boosting, the productions of all tubulysins decreased. The explanation might be the 
orf17 knockout affects the normal transcription of its overlapped neighbor gene tubF, resulting in 
the decline of tubulysin productions. 
 
 
4.5   Heterologous expression of tubulysin pathway 
 
   I have applied Red/ET recombineering to reconstitute the 11 gene tubulysin cluster from two 
cosmids. Addition of a transposon was carried out to facilitate the transformation in other host 
strains. The stitched cluster was then transferred into two heterologous hosts, Pseudomonas 
putida and the myxobacterium Myxococcus xanthus. They majorly produce pretubulysin A and 
tyrosine pretubulysin A, the predicted products of the gene cluster. The yields of tubulysins in 
both heterologous expression strains are lower than those of the natural producer strains even they 
were supplied with sufficient starter unit pipecolic acid.  
    
   The established heterologous expression system provides a good platform that can be used to 
manipulate the tubulysin gene cluster in E.coli strain, which makes the investigation of tubulysin 
pathway much easier than before. Generating the equivalent mutations (such as tubA, orf1, tubZ 
and orf2) in the heterologous expression system in host strain M. xanthus DK1622 was a good 
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application, particularly for the small gene orf2. In the natural producer myxobacterial strains, it 
was difficult to knock out such a small gene. But in the heterologous expression system, the gene 
engineering only happens in E. coli strain, making it much easier.  
 
 
4.6   Searching the missing monooxygenase in the SBCb004 genome  
 
   Although the identified tubulysin cluster gives rise to bioactive pathway intermediates, it lacks 
the post-modification oxidase and/or acyl transferase functions responsible for generating mature 
tubulysins. By BLAST analysis of the SBCb004 genome, multiple candidate monooxygenases 
were identified by annotation of their flanking regions. The involvements of selected seven 
monooxygenases in tubulysin assembly were investigated using knockout mutagenesis. 
 
   A mutant of a P450 gene from contig 633 (633P1) was found out to produce only the 
pretubulysin subfamily compounds 14, 18, 20, and 28 at dramatically decreased amount, and the 
tubulysin variants incorporating post-PKS hydroxylation were completely absent. This result 
makes gene 633P1 the most promising candidate for one of the missing oxygenases, even though 
it is still unclear why the pretubulysins’ yield is also affected by 633P1 inactivation. 
 
   To attempt to confirm the involvement of gene 633P1 in tubulysin biosynthesis, the 
heterologeous expression system was employed too. 633P1 was introduced into the heterologous 
expression construct and co-expressed with the tubulysin gene cluster in P. putida. Unfortunately, 
the tubulysin production profile with 633P1 was the same as before. It is possible that the P450 
enzyme requires additional gene products to be present in order to be active during the tubulysin 
assembly, which are currently absent from the heterologous expression construct (e.g. ferredoxins 
and ferredoxin reductases).  
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